<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="review-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">50740</article-id><article-id pub-id-type="doi">10.7554/eLife.50740</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Preclinical murine tumor models: A structural and functional perspective</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-169508"><name><surname>Guerin</surname><given-names>Marion V</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2159-8518</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169509"><name><surname>Finisguerra</surname><given-names>Veronica</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2455-9939</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169510"><name><surname>Van den Eynde</surname><given-names>Benoit J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4995-3270</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30296"><name><surname>Bercovici</surname><given-names>Nadege</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8449-0590</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-29822"><name><surname>Trautmann</surname><given-names>Alain</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7514-420X</contrib-id><email>alain.trautmann@inserm.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, F-75014</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Ludwig Institute for Cancer Research, de Duve Institute WELBIO</institution><institution>UCLouvain</institution><addr-line><named-content content-type="city">Brussels</named-content></addr-line><country>Belgium</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Settleman</surname><given-names>Jeffrey</given-names></name><role>Senior Editor</role><aff><institution>Pfizer</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Kawakami</surname><given-names>Yutaka</given-names></name><role>Reviewing Editor</role><aff><institution>Keio University School of Medicine</institution><country>Japan</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>28</day><month>01</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e50740</elocation-id><history><date date-type="received" iso-8601-date="2019-08-02"><day>02</day><month>08</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-01-06"><day>06</day><month>01</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Guerin et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Guerin et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-50740-v1.pdf"/><abstract><p>The goal of this review is to pinpoint the specific features, including the weaknesses, of various tumor models, and to discuss the reasons why treatments that are efficient in murine tumor models often do not work in clinics. In a detailed comparison of transplanted and spontaneous tumor models, we focus on structure–function relationships in the tumor microenvironment. For instance, the architecture of the vascular tree, which depends on whether tumor cells have gone through epithelial-mesenchymal transition, is determinant for the extension of the spontaneous necrosis, and for the intratumoral localization of the immune infiltrate. Another key point is the model-dependent abundance of TGFβ in the tumor, which controls the variable susceptibility of different tumor models to treatments. Grounded in a historical perspective, this review provides a rationale for checking factors that will be key for the transition between preclinical murine models and clinical applications.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>transplanted tumors</kwd><kwd>spontaneous tumors</kwd><kwd>TGFβ</kwd><kwd>vascularization</kwd><kwd>EMT</kwd><kwd>microenvironment</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003023</institution-id><institution>Ministère de l'Éducation Nationale</institution></institution-wrap></funding-source><award-id>Graduate Student Fellowship</award-id><principal-award-recipient><name><surname>Guerin</surname><given-names>Marion V</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011713</institution-id><institution>Worldwide Cancer Research</institution></institution-wrap></funding-source><award-id>AICR # 13–0260</award-id><principal-award-recipient><name><surname>Trautmann</surname><given-names>Alain</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004099</institution-id><institution>Ligue Contre le Cancer</institution></institution-wrap></funding-source><award-id>RS18/75-61</award-id><principal-award-recipient><name><surname>Bercovici</surname><given-names>Nadege</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004794</institution-id><institution>Centre National de la Recherche Scientifique</institution></institution-wrap></funding-source><award-id>Core funding</award-id><principal-award-recipient><name><surname>Bercovici</surname><given-names>Nadege</given-names></name><name><surname>Trautmann</surname><given-names>Alain</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001677</institution-id><institution>Inserm</institution></institution-wrap></funding-source><award-id>Core funding</award-id><principal-award-recipient><name><surname>Bercovici</surname><given-names>Nadege</given-names></name><name><surname>Trautmann</surname><given-names>Alain</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005413</institution-id><institution>Paris Descartes University</institution></institution-wrap></funding-source><award-id>Core funding</award-id><principal-award-recipient><name><surname>Bercovici</surname><given-names>Nadege</given-names></name><name><surname>Trautmann</surname><given-names>Alain</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002661</institution-id><institution>Fonds De La Recherche Scientifique - FNRS</institution></institution-wrap></funding-source><award-id>28095636</award-id><principal-award-recipient><name><surname>Finisguerra</surname><given-names>Veronica</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Dissecting structural, cellular and molecular differences between transplanted and spontaneous mouse tumor models, highlighting their relevance for predicting the efficacy of anti-cancer treatments in patients.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Murine tumor models have proven to be useful for our understanding of biological processes that take place during tumor growth, and for the preclinical development of antitumor therapies. However, the limitations of these models are too frequently overlooked. As a result, numerous anti-tumor drugs that were shown to be efficient in mice ended up being unusable against human tumors. Even if such a major failure has already been discussed, this problem still needs to be examined in depth. A large part of this review will be devoted to comparing the properties of spontaneous (SP) and transplanted (TP) tumors. We will take advantage of two models (a mammary tumor and a melanoma), in which TP and SP tumors can be obtained with isogenic tumor cells. This comparison will be made for the first time by taking into account global structural and functional points of view. Structural features are those that affect the tumor architecture, which is largely dependent on the pre-existence of an epithelial to mesenchymal transition (EMT). For the functional analysis in TP and SP tumors, we examine a series of key tumor features: vascularization, growth rate, immune infiltrate and inflammation, tumor metabolism, and influence of tumor-derived TGFβ. We evaluate the influence of these features on spontaneous growth rate and, most importantly, on the sensitivity of tumors to various treatments, as summarized in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Structural and functional comparison of SP and TP tumors.</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" valign="top"/><th valign="top">SP vs TP</th><th valign="top">Subcutaneous (s.c.) TP vs orthotopic (ortho.)TP</th><th valign="top">References</th></tr></thead><tbody><tr><td colspan="2">Vasculature fragility</td><td valign="top">TP &gt; SP</td><td align="center" valign="top">Ortho &gt; s.c.</td><td valign="top"><xref ref-type="bibr" rid="bib46">Fenton et al. (2001)</xref>; <xref ref-type="bibr" rid="bib37">Drees et al. (2015)</xref>; <xref ref-type="bibr" rid="bib64">Guerin et al. (2019)</xref>; <xref ref-type="bibr" rid="bib56">Fung et al. (2015)</xref></td></tr><tr><td colspan="2">Vasculature growth rate</td><td valign="top">TP &gt; SP</td><td align="center" valign="top"/><td valign="top">This review</td></tr><tr><td colspan="2">Tumor architecture</td><td valign="top">SP &gt; TP <break/>SP = TP</td><td align="center" valign="top"/><td valign="top">This review <break/><xref ref-type="bibr" rid="bib141">Weiss et al. (2017)</xref>; <xref ref-type="bibr" rid="bib64">Guerin et al. (2019)</xref></td></tr><tr><td colspan="2">Tumor growth rate</td><td valign="top">TP &gt; SP <break/>TP = SP</td><td align="center" valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib143">Wexler et al. (1965)</xref>; <xref ref-type="bibr" rid="bib90">McCredie et al. (1971)</xref>; <xref ref-type="bibr" rid="bib108">Rous (1914)</xref>; <xref ref-type="bibr" rid="bib15">Burton and Begg (1961)</xref>; <xref ref-type="bibr" rid="bib150">Zhu et al. (2017)</xref></td></tr><tr><td colspan="2">TGFβ abundance</td><td valign="top">SP &gt; TP</td><td align="center" valign="top">Ortho &gt; s.c.</td><td valign="top"><xref ref-type="bibr" rid="bib64">Guerin et al. (2019)</xref>; <xref ref-type="bibr" rid="bib150">Zhu et al. (2017)</xref>; <xref ref-type="bibr" rid="bib24">Choudhury et al. (2004)</xref></td></tr><tr><td colspan="2">Spontaneous immune response</td><td valign="top">TP &gt; SP</td><td align="center" valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib4">Anders et al. (2017)</xref></td></tr><tr><td colspan="2">Tumor-associated macrophage (TAM) renewal rate</td><td valign="top">TP &gt; SP</td><td align="center" valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib121">Strachan et al. (2013)</xref>; <xref ref-type="bibr" rid="bib54">Franklin et al. (2014)</xref></td></tr><tr><td colspan="2">Myeloid-derived suppressor cell (MDSC) abundance</td><td valign="top">SP &gt; TP</td><td align="center" valign="top">Ortho &gt; s.c.</td><td valign="top"><xref ref-type="bibr" rid="bib26">Coffelt and de Visser (2015)</xref>; <xref ref-type="bibr" rid="bib150">Zhu et al. (2017)</xref>; <xref ref-type="bibr" rid="bib64">Guerin et al. (2019)</xref>; <xref ref-type="bibr" rid="bib33">Devaud et al. (2014)</xref></td></tr><tr><td align="left" rowspan="6">Sensitivity to</td><td>Immunogenic cell death (ICD)-based chemotherapy</td><td valign="top">TP only</td><td align="center" valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib25">Ciampricotti et al. (2012)</xref>; <xref ref-type="bibr" rid="bib26">Coffelt and de Visser (2015)</xref></td></tr><tr><td>Stimulator of interferon genes protein (STING) agonists</td><td valign="top">TP only</td><td align="center" valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib64">Guerin et al. (2019)</xref></td></tr><tr><td>Adoptive transfer of T cells</td><td valign="top">TP &gt; SP</td><td align="center" valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib150">Zhu et al. (2017)</xref></td></tr><tr><td>Vaccination</td><td valign="top">TP only</td><td align="center" valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib96">Old et al. (1961)</xref>; <xref ref-type="bibr" rid="bib69">Hirsch (1962)</xref>; <xref ref-type="bibr" rid="bib106">Reilly et al. (2000)</xref>; <xref ref-type="bibr" rid="bib40">Ercolini et al. (2003)</xref></td></tr><tr><td>Cortisone</td><td valign="top">TP &gt; SP</td><td align="center" valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib15">Burton and Begg (1961)</xref></td></tr><tr><td>Interleukin-12 (IL-12)</td><td valign="top">TP only</td><td valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib83">Lee et al. (2002)</xref></td></tr></tbody></table></table-wrap><p>The fact that different tumor models may not be equivalent is an issue that was first recognized a long time ago. One of the first to address this problem was Francis Peyton Rous, well before the Nobel prize that he obtained in 1966 for his work on virus-induced tumors. In 1914, FP Rous examined the extent to which the mouse diet could influence tumor growth rate in SP and TP tumors (<xref ref-type="bibr" rid="bib108">Rous, 1914</xref>). He concluded that starvation slows down tumor growth, by affecting both the tumor and its stroma. Importantly, he pointed out that results obtained in these SP and TP systems differ and that 'generalizations from work with transplanted tumors as regards the effects of diet on spontaneous growths are unwarranted’.</p><p>Since then, the specific features of different tumor models have been discussed in several reviews (<xref ref-type="bibr" rid="bib115">Sharpless and Depinho, 2006</xref>; <xref ref-type="bibr" rid="bib127">Talmadge et al., 2007</xref>; <xref ref-type="bibr" rid="bib26">Coffelt and de Visser, 2015</xref>; <xref ref-type="bibr" rid="bib97">Olson et al., 2018</xref>), often with a focused scope, such as a comparison between the different types of genetically engineered mice models (GEMM) designed to develop so-called ‘spontaneous’ tumors. Before starting the comparison between TP and SP tumors, it is necessary to have a global vision of the wide variety of murine tumor models.</p></sec><sec id="s2"><title>Variety of transplanted tumors</title><p>The diversity of TP tumors stems from the <italic>origin</italic> and the <italic>type of cells</italic> that are implanted, their <italic>abundance</italic> and their <italic>site of implantation</italic> (subcutaneous or orthotopic). These tumor cells may be established cell lines, primary tumor cells freshly dissociated from spontaneous tumors, or fragments of tumors transferred from donor to host animals. In the latter two cases, transplanted cells include different cell types present in the tumor microenvironment. In the two isogenic models that are examined in this review, the TP tumors developed after implantation of a tumor cell line in one case (the melanoma), whereas TP tumors in the PyMT mammary model developed after transplantation of dissociated SP tumors.</p><sec id="s2-1"><title>Syngeneic tumors versus xenografts</title><p>In a vast majority of studies with TP tumors, tumor cells are grafted in syngeneic mice. If a treatment proves to be efficient in such preclinical settings, the translation to clinical studies often presents difficulties, because the molecular tools developed in the murine models cannot always be used for humans. For instance, the STING agonist DMXAA (5,6-dimethylxanthenone-4-acetic acid), which destroys tumor vessels in TP murine tumors quite efficiently, is totally devoid of effects against the vasculature of human tumors. This difference is mainly due to the fact that DMXAA action in TP tumors requires STING binding and activation; however, this molecule does not bind at all to human STING (<xref ref-type="bibr" rid="bib28">Conlon et al., 2013</xref>). This explains the total absence of effects of DMXAA in a Phase III clinical trial involving almost 1300 patients (<xref ref-type="bibr" rid="bib81">Lara et al., 2011</xref>). Even when compatible with human molecules, STING agonists may still not work in clinical trials given their inefficacy in SP tumors compared to TP models, as will be discussed below. The species specificity of molecular tools is also true for a large panel of antibodies and engineered constructs, such as chimeric antigen receptors (CAR).</p><p>For these reasons, pharmaceutical companies have encouraged the use of human xenografts, that is of human tumor cells grafted in immunocompromised mice. Their obvious advantage is the immediate availability for clinical studies of the molecular tools developed in the preclinical studies. The reasoning was sound when the field was dominated by oncologic approaches targeting first tumor cells. However, the obligation to use immunocompromised mice (either RAG<sup>–/–</sup>, <italic>Scid</italic>, NOD or NSG) that will tolerate the xenograft is now considered to be a major drawback. Indeed, most anti-tumoral treatments, including chemotherapy, radiotherapy, or adoptive transfer of CAR T cells, clearly need to stimulate endogenous immune cells for optimal efficacy. In immunodeficient mice, the absence of T cells and, eventually, of additional types of immune cells, severely limits the usefulness of models based on xenografted tumors. This may explain why preclinical models based on human xenografts have failed to predict the clinical efficacy of most of the therapies targeted to cancer-driving proteins (<xref ref-type="bibr" rid="bib31">Day et al., 2015</xref>).</p><p>It is theoretically possible to circumvent this problem by using humanized mice. However, because immune responses involve many different cell types, obtaining a mouse with a fully humanized immune system is very complicated (<xref ref-type="bibr" rid="bib97">Olson et al., 2018</xref>). Moreover, for humanization to be complete, it should be extended to other cells of the tumor microenvironment, that is endothelial cells and stromal cells. The complexity and the resulting cost of such mice are both huge.</p></sec><sec id="s2-2"><title>Subcutaneous versus orthotopic implantation</title><p>The advantage of implanting tumor cells subcutaneously is that the size of these tumors is easier to measure than that of visceral tumors. However, numerous papers have shown that tumor growth, vascularization and sensitivity to anti-tumoral treatments are dependent upon the site of implantation. Thus, there are fewer functional blood vessels in orthotopic tumors than in subcutaneous tumors, as measured with a perfusion marker (<xref ref-type="bibr" rid="bib56">Fung et al., 2015</xref>). Compared to subcutaneous tumors, orthotopic tumors are more immunosuppressive in nature, with a larger abundance of alternatively activated macrophages, and they are less sensitive to immunotherapy than subcutaneous tumors (<xref ref-type="bibr" rid="bib33">Devaud et al., 2014</xref>). This difference could be related to the fact that TGFβ is present in tumors derived from orthotopic but not subcutaneous implantation, as shown in a pancreatic cell line (<xref ref-type="bibr" rid="bib24">Choudhury et al., 2004</xref>). Note that TGFβ is frequently present in SP tumors, as discussed by <xref ref-type="bibr" rid="bib64">Guerin et al. (2019)</xref>, and from this point of view, orthotopic TP tumors are more similar than subcutaneous TP ones to SP models.</p></sec></sec><sec id="s3"><title>Variety of spontaneous tumors</title><p>Even if this review is devoted to the analysis of murine tumor models, it is worth remembering that other tumor models could also deserve consideration (<xref ref-type="box" rid="box1">Box 1</xref>). SP tumors may develop with aging in some strains of non-transgenic laboratory animals that have been selected for being cancer-prone. They constitute a first type of SP or autochthonous tumors. This is the case, for instance, for one-year- old C3H female mice, which often develop one or two mammary tumors (<xref ref-type="bibr" rid="bib139">Waxler et al., 1953</xref>).</p><p>Amongst different strains of laboratory mice, a negative correlation has been established between the probability of developing such tumors and the efficacy of the immune system. This efficacy was evaluated by the strength of the immune responses triggered by sheep red blood cells. This correlation could indicate that cancer formation is a relatively frequent process that is counterbalanced by immune surveillance (<xref ref-type="bibr" rid="bib55">Frese and Tuveson, 2007</xref>).</p><p>Oncogene-induced tumors, which develop in GEMM, constitute a second type of murine SP tumors. A number of reviews have been devoted to the properties of different GEMM, the most frequently used model of SP tumors, for cancer studies ( <xref ref-type="bibr" rid="bib55">Frese and Tuveson, 2007</xref>; <xref ref-type="bibr" rid="bib145">Willimsky and Blankenstein, 2007</xref>; <xref ref-type="bibr" rid="bib31">Day et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Kersten et al., 2017</xref>; <xref ref-type="bibr" rid="bib97">Olson et al., 2018</xref>). Oncogene-induced tumors present a high incidence, which leads to a delay of only a few weeks between birth and tumor development. Different GEMM have been constructed to generate tumors in various organs. For instance, mammary tumors develop ‘spontaneously’ in models where an oncogene (either PyMT or <italic>neu</italic>) is targeted to the mammary glands by the inclusion in the oncogene promoter of MMTV, that is Mouse mammary tumor virus (MMTV-PyMT or MMTV-neu mice).</p><p>In MMTV-PyMT mice, up to 10 tumors develop with a delay of 2 months in FVB mice, and of 5 months in C57BL/6J mice. Similarly, oncogene-driven tumors are generated in the prostate in the TRAMP model (<xref ref-type="bibr" rid="bib53">Foster et al., 1997</xref>) and in the pancreas in the Rip-Tag model (<xref ref-type="bibr" rid="bib147">Ye et al., 1994</xref>), whereas melanoma tumors are developed in the Ret model (<xref ref-type="bibr" rid="bib126">Takahashi et al., 1992</xref>). In some variants of these GEMM, such as the TiRP (Tamoxifen-Induced, expressing active Ras and the P1A tumor-specific antigen) melanoma model, the expression of the oncogenes is induced, for instance by tamoxifen (<xref ref-type="bibr" rid="bib72">Huijbers et al., 2006</xref>; <xref ref-type="bibr" rid="bib76">Kersten et al., 2017</xref>; <xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>). In practice, inducible models are somehow intermediate between TP and SP oncogene-induced tumors. Like TP tumors, their triggering is sudden, but, as for oncogene-induced tumors that develop with aging, there is no massive introduction of tumor cells, many of which die and trigger an inflammatory situation.</p><boxed-text id="box1"><label>Box 1.</label><caption><p>Tumor models in different animals.</p></caption><p>When considering other animal tumor models, the Sprague-Dawley rat is a strain well-known to develop spontaneous endocrine tumors (<xref ref-type="bibr" rid="bib125">Suzuki et al., 1979</xref>). There is also a strain of small pigs that have been selected for their propensity to develop spontaneous melanoma, which often regress spontaneously (<xref ref-type="bibr" rid="bib98">Oxenhandler et al., 1982</xref>; <xref ref-type="bibr" rid="bib101">Pérez et al., 2002</xref>). The mechanisms underlying this spontaneous regression have never been studied in detail, which is a pity given the proximity of the immune systems of humans and pigs. By contrast, there are animals that almost never develop cancers, such as mole rats, which is remarkable, given their exceptional longevity (frequently &gt;30 years) (<xref ref-type="bibr" rid="bib34">Deweerdt, 2014</xref>). The analysis of these other animal models is of major interest, but beyond the scope of this review.</p></boxed-text><p>One may consider that the incidence of these GEMM tumors is excessively high, and results in multifocal or multiple tumors, which develop much faster than those in humans. This is why T. Blankenstein and colleagues have developed a third model, the so-called sporadic tumor model, which is still oncogene-induced but with such a low probability that only one or two tumors develop, after a long delay in the order of one year. This model is certainly as close as possible to human tumors (<xref ref-type="bibr" rid="bib145">Willimsky and Blankenstein, 2007</xref>; <xref ref-type="bibr" rid="bib144">Willimsky and Blankenstein, 2005</xref>).</p><p>Given their dependency on specific genetic events, GEMM have proved to be useful for testing the efficacy of agents targeting farnesyl transferase, epidermal growth factor receptor, angiogenesis, matrix metalloproteases and vascular endothelial growth factor (VEGF) to inhibit tumor growth (<xref ref-type="bibr" rid="bib133">Van Dyke and Jacks, 2002</xref>; <xref ref-type="bibr" rid="bib122">Suggitt and Bibby, 2005</xref>; <xref ref-type="bibr" rid="bib77">Kohl et al., 1995</xref>; <xref ref-type="bibr" rid="bib85">Lenferink et al., 2000</xref>; <xref ref-type="bibr" rid="bib8">Bergers et al., 1999</xref>; <xref ref-type="bibr" rid="bib9">Bergers et al., 2000</xref>; <xref ref-type="bibr" rid="bib73">Huss et al., 2003</xref>). Moreover, GEMM also make it possible to evaluate how mutations in specific genes affect tumor sensitivity or resistance to chemotherapeutic drugs, such as cyclophosphamide in lymphoid malignancy (<xref ref-type="bibr" rid="bib111">Schmitt et al., 1999</xref>) or doxorubicin and paclitaxel in mammary and salivary tumors (<xref ref-type="bibr" rid="bib6">Bearss et al., 2000</xref>).</p><p>However, by construction, the mutational burden of tumors in GEMM is usually low compared to that observed in human tumors. To reduce this gap, it has been proposed that the mutation load in GEMM should be increased, for instance by introducing mutations in the DNA mismatch repair machinery (<xref ref-type="bibr" rid="bib59">Germano et al., 2017</xref>). An additional difference between GEMM and human tumors should be noted: a human tumor is expected to correspond to the descendance of one or a few initially transformed cells, whereas in a GEMM, the constitutive expression of a few oncogenes maintains the continuous appearance of newly transformed cells. A single stream is not equivalent to multiple streams that are constantly renewed.</p></sec><sec id="s4"><title>Carcinogen-induced tumors and metastases</title><p>In addition to the TP and SP models, tumors may also be induced by a carcinogen, either chemical or mineral/mechanical (asbestos). In carcinogen-induced models, the type and route of administration of the carcinogen dictates the location in which the tumor is formed. For instance, topical application of DMBA/TPA (7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate) results in skin carcinogenesis, and injection of methylcholanthrene (MCA) intramuscularly gives rise to fibrosarcomas. Carcinogen-induced tumors show a strong and long-lasting inflammation (<xref ref-type="bibr" rid="bib117">Shi et al., 2017</xref>) that resembles the chronic inflammatory milieu of GEMM such as the K14-HPV16 transgenic model of skin carcinogenesis (<xref ref-type="bibr" rid="bib32">de Visser et al., 2005</xref>).</p><p>Given the fact that most carcinogens are also mutagenic agents, carcinogen-induced tumors have a higher mutational burden compared to GEMM or TP models, which are most often genetically defined by two or three mutations (<xref ref-type="bibr" rid="bib97">Olson et al., 2018</xref>). Consistent with the fact that a high mutation load increases the occurrence of neoantigens recognizable by a large number of T cells (<xref ref-type="bibr" rid="bib22">Chan et al., 2019</xref>), thus influencing the importance of the T cell infiltrate, tumor patients with high mutational burden usually show a good response to immunotherapy (<xref ref-type="bibr" rid="bib82">Lawrence et al., 2013</xref>; <xref ref-type="bibr" rid="bib2">Alexandrov et al., 2013</xref>; <xref ref-type="bibr" rid="bib104">Quiroga et al., 2016</xref>; <xref ref-type="bibr" rid="bib21">Chalmers et al., 2017</xref>; <xref ref-type="bibr" rid="bib112">Schumacher and Schreiber, 2015</xref>; <xref ref-type="bibr" rid="bib63">Gros et al., 2016</xref>; <xref ref-type="bibr" rid="bib114">Sharma and Allison, 2015</xref>; <xref ref-type="bibr" rid="bib91">McGranahan et al., 2016</xref>). The higher immunogenicity of carcinogen-induced tumors compared to GEMM tumors has been illustrated by studies showing that sarcomas triggered by KrasG12D oncogene activation and Trp53 deletion are not recognized by the immune system, contrary to the MCA-induced mouse model of sarcoma, which may induce the appearance of tumor-specific T cells (<xref ref-type="bibr" rid="bib38">DuPage et al., 2012</xref>; <xref ref-type="bibr" rid="bib89">Matsushita et al., 2012</xref>). In addition, MCA-induced mouse sarcomas harbor genetic mutations similar to those found in patients bearing tumors that are likely to be carcinogen-induced (<xref ref-type="bibr" rid="bib86">Liu et al., 2014</xref>).</p><p>Given the importance of tumor immunogenicity in predicting the response to immunotherapies, carcinogen-induced tumor models would be of interest for investigating the efficacy of immunotherapeutic agents. In addition, and contrary to what happens in TP models, carcinogen-induced tumors and SP tumors share the relative slowness of their development, which allows the formation of a complex tumor microenvironment (<xref ref-type="bibr" rid="bib97">Olson et al., 2018</xref>). However, carcinogen-induced models have been employed in only a minority of immunotherapy pre-clinical studies. See for instance, a study on the synergistic effect of anti-CD73 and anti-PD-1 treatment in delaying progression of MCA-induced fibrosarcomas (<xref ref-type="bibr" rid="bib3">Allard et al., 2013</xref>). The delayed development, heterogeneous appearance, location, size and number of carcinogen-induced tumors contribute not only to the biological interest but also to the experimental complexity of these tumor models (<xref ref-type="bibr" rid="bib87">Liu et al., 2015</xref>). These features of carcinogen-induced models, which are less marked but comparable to those observed with sporadic tumor models, make it difficult to produce homogeneous groups of animals that can be used to compare therapeutic modalities.</p><p>Transplanted cell lines that are derived from carcinogen-induced tumors have been more commonly used (<xref ref-type="bibr" rid="bib39">Efremova et al., 2018</xref>; <xref ref-type="bibr" rid="bib105">Redmond et al., 2014</xref>; <xref ref-type="bibr" rid="bib95">Noguchi et al., 2017</xref>). One may expect that such tumor cells have a higher mutational burden than other TP cell lines, and could potentially be more immunogenic. However, the rapid growth of such tumors is typical of TP tumors, with a quickly built microenvironment. This will put limits on their clinical relevance, as further discussed later.</p><p>All of the examples given above concern primary tumors, and not metastases, which constitute a problem of major importance because most cancer patients die of metastases, not of their primary tumors. The use of murine models for studying the formation and treatment of metastases is too important and specific a topic to fit within the scope of the present review, and will not be further examined here.</p></sec><sec id="s5"><title>Comparing TP and SP tumors</title><p>Now that the global landscape of tumor models has been recalled, we can begin to compare them. The discussion will focus on comparing TP and SP tumors, by examining the different <italic>functional</italic> aspects of the tumors that appear to be model-dependent. Up to now, such comparisons have mainly dealt with differences in the vasculature of TP and SP tumors (<xref ref-type="bibr" rid="bib44">Falk, 1982</xref>; <xref ref-type="bibr" rid="bib46">Fenton et al., 2001</xref>; <xref ref-type="bibr" rid="bib47">Fenton et al., 2004</xref>; <xref ref-type="bibr" rid="bib118">Sikder et al., 2003</xref>; <xref ref-type="bibr" rid="bib83">Lee et al., 2002</xref>). Here, we underline the importance of not only the vasculature but also the tumor's growth rate, immune infiltrate, inflammation level, metabolism, and TGFβ signaling, and how these characteristics influence tumor sensitivity to anti-cancer treatments (as summarized in <xref ref-type="table" rid="table1">Table 1</xref>). We also highlight the variability observed for different features. This variability does not result from some inaccuracy in the measurements. It rather reflects the importance of stochasticity in life, which has been taken into account in several complementary concepts: first in Darwin’s theory of natural selection of random variants, then in the notions of ‘epigenetic landscape’ (<xref ref-type="bibr" rid="bib136">Waddington, 1957</xref>), ‘gene network dynamics’, multi-stability and self-organization, which allow a given living system to adopt several possible stable states (<xref ref-type="bibr" rid="bib70">Huang, 2012</xref>). A phenotype is not determined by genotype alone but also by constraints including stochastic events and epigenetics. Therefore, the ‘variability’ that is inherent to some tumor models should not be concealed.</p><sec id="s5-1"><title>Vascularization</title><p>Using various approaches (<xref ref-type="box" rid="box2">Box 2</xref>), several steps in tumor angiogenesis have been distinguished. This process starts with proliferative endothelial cells that sprout from pre-existing blood vessels, giving rise to uncovered blood vessels of small diameter. The newly formed blood vessels subsequently expand by means of endothelial cell proliferation and migration to form larger blood vessels, which are progressively covered by pericytes. Contrary to the initial uncovered sprouts, these larger mature vessels are formed by quiescent endothelial cells that have limited proliferation and sprouting (<xref ref-type="bibr" rid="bib58">Gee et al., 2003</xref>). However, all of these processes are often deregulated at cellular and molecular levels in cancer, giving rise to a heterogeneous, disorganized and misshaped vessel network, which is aberrantly covered by pericytes and therefore poorly functional (<xref ref-type="bibr" rid="bib84">Leite de Oliveira et al., 2011</xref>). From tumor to tumor, and for reasons mentioned above, a huge variability is observed in the detailed shape of the vascular network and in the size of its meshes.</p><p>Angiogenesis of small tumors is more active than that of large tumors, and the vascular tree is more immature in small tumors. This could explain why small tumors are more sensitive to anti-angiogenic treatments than large ones (<xref ref-type="bibr" rid="bib58">Gee et al., 2003</xref>). Both SP and TP tumors may be responsive to anti-angiogenic treatments (<xref ref-type="bibr" rid="bib46">Fenton et al., 2001</xref>), but the response in SP models varies from tumor to tumor (<xref ref-type="bibr" rid="bib47">Fenton et al., 2004</xref>; <xref ref-type="bibr" rid="bib48">Fenton et al., 2005</xref>; <xref ref-type="bibr" rid="bib64">Guerin et al., 2019</xref>). Endoplasmic reticulum (ER) stress is a major consequence of defective tumoral vascularization and resulting hypoxia. This stress, which has been measured in vivo with a bioluminescent probe in a model of multiple mammary primary tumors, displays a marked variability between the different tumors of the same mouse and correlates positively with tumor growth rate (<xref ref-type="bibr" rid="bib120">Spiotto et al., 2010</xref>).</p><p>A fundamental difference between the vascularization of SP and TP tumors is the ‘<italic>angiogenic switch</italic>’ (<xref ref-type="bibr" rid="bib52">Folkman and Hanahan, 1991</xref>), that is the point at which angiogenesis becomes actively sustained by the tumor microenvironment through the secretion of pro-angiogenic molecules by tumor cells and macrophages, thus perturbing the local balance between anti-angiogenic and pro-angiogenic factors (<xref ref-type="bibr" rid="bib50">Folkman, 1971</xref>; <xref ref-type="bibr" rid="bib51">Folkman, 2002</xref>). SP tumors can only grow after this switch has taken place (<xref ref-type="bibr" rid="bib65">Hanahan and Folkman, 1996</xref>). In TP models, tumor cells have already switched. Therefore, immediately after their implantation, they start to produce the pro-angiogenic factors necessary for blood supply and tumor growth. As soon as 18 hr after implantation, the beginnings of vascularization in TP tumors may be directly observed through a window chamber (<xref ref-type="bibr" rid="bib146">Wood, 1958</xref>).</p><boxed-text id="box2"><label>Box 2.</label><caption><p>Analyzing tumor vascularization.</p></caption><p>Tumor vessel morphology and functionality can be studied in different ways, for instance by the immunostaining of tumor sections for endothelial cell markers (CD31<sup>+</sup>, Tie-2<sup>+</sup>), alone or combined with markers for proliferation (PCNA<sup>+</sup>) or apoptosis (active caspase 3) that are used to identify proliferating or apoptotic endothelial cells, respectively. Tumor vessel coverage and stability can be investigated by combining endothelial cell staining with laminin or pericyte (α-SMA<sup>+</sup>) staining. Vessel perfusion or vessel leakage can be assessed by intravenous injection of fluorescently labelled lectin or 70-KDa dextran molecules, a few minutes before sacrificing the mice. The perfusion of surrounding tissues can be evaluated by injecting Hoechst 33342 5 min before the sacrifice. The hypoxic probe pimonidazole or the hypoxic marker (CAIX) allows the identification of hypoxic tumor areas. Vessel ultrastructure can be studied by scanning and transmission electron microscopy.</p></boxed-text><p>Another difference in the vascularization of SP and TP tumors is related to the multifocal origin of TP tumors after the simultaneous implantation of tens or hundreds of thousands of tumor cells. This multifocality influences the architecture of the vascular network (<xref ref-type="bibr" rid="bib44">Falk, 1982</xref>).</p><p>Compared to slow SP tumors, the rapidly growing TP tumors are likely to have more immature blood vessels that are more sensitive to inflammatory cytokines such as TNFα, which may be produced following a bacterial infection. By inducing vascular disruption, TNFα and other pro-inflammatory cytokines could facilitate bacterial tumor-colonization. The different vasculature structure in TP and SP tumors may explain why, after systemic administration of <italic>Salmonella typhimurium</italic>, which are bacteria with reported tumor-targeting propensity, bacterial colonization was higher in TP than in SP tumors. As a result, <italic>S. typhimurium</italic> may exert an oncolytic action against TP but not against SP tumors (<xref ref-type="bibr" rid="bib37">Drees et al., 2015</xref>). In line with the observation in SP models, clinical studies showed lack of tumor colonization by the <italic>Salmonella typhimurium</italic> strain VNP20009, again underlying how transplanted tumors do not always mimic the autochthonous tumors that develop in SP models or in patients (<xref ref-type="bibr" rid="bib37">Drees et al., 2015</xref>).</p></sec><sec id="s5-2"><title>Tumor architecture</title><p>After tumor initiation, stromal cells may be recruited by the nascent tumor from neighboring normal tissue or may differentiate from mesenchymal cells arriving through the blood from the bone marrow (<xref ref-type="bibr" rid="bib13">Bucala et al., 1994</xref>; <xref ref-type="bibr" rid="bib78">Kraman et al., 2010</xref>). The self-organization of the stroma involves different cell types including stromal cells, endothelial cells and macrophages. The stromal compartment usually includes a peritumoral capsule and stromal sheets between tumor islets. This organization is typical of human carcinoma and it is also observed in some murine tumor models (see below). In the MMTV-PyMT (pre-EMT) model, fibronectin is only expressed by stromal cells, and the vasculature is strictly associated with the stroma. This holds true whether the tumor is SP, or whether it results from an orthotopical implant (TP) of cells freshly dissociated from a SP tumor (<xref ref-type="fig" rid="fig1">Figure 1A&amp;B</xref>) and thus includes multiple cell types that have not been kept in culture. However, in most commonly used models of TP tumors, 10<sup>5</sup>–10<sup>6</sup> cells from an established tumor cell line are injected subcutaneously. Cells kept in culture for a long time usually drift, and such tumor cell lines have frequently acquired fibroblast markers such as gp38 or fibronectin because they have gone through EMT. An example is provided by the TC1 (TP) tumor model (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Post-EMT tumor cells never form tumors that are organized into tumor islets and stromal sheets, as if the self-organization of the stromal compartment were hampered by the similarities between fibroblasts and post-EMT tumor cells. Moreover, a mesenchymal transition may sometimes take place in vivo. This is the case for a SP melanoma model named TiRP described in <xref ref-type="bibr" rid="bib150">Zhu et al. (2017)</xref> (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). This tumor shows a uniform fibronectin expression and no tumor islets nor stromal sheets. The same structure is observed in the corresponding TP melanoma (not shown).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Fibronectin expression is restricted to stromal cells in PyMT tumors, but not in tumors that have undergone EMT.</title><p>In the MMTV-PyMT model, fibronectin is only expressed by stromal cells, if the tumor is (<bold>A</bold>) spontaneous (SP) or (<bold>B</bold>) results from an orthotopical implant (TP) of cells dissociated from a SP tumor. Fibronectin may also be expressed by all tumor cells after EMT has taken place in (<bold>C</bold>) the TC1 cell line, here transplanted subcutaneously, or in (<bold>D</bold>) a spontaneous melanoma, TiRP. Tumor pieces were fixed overnight with periodate-lysine-paraformaldehyde at 4°C. Then, tumor samples were embedded in 5% low-gelling temperature agarose prepared in phosphate-buffered saline (PBS). 350 μm slices were cut with a vibratome in a bath of ice-cold PBS. Immunostaining of surface markers was performed at 37°C for 15 min with antibodies specific to EpCAM-BV421, CD31-Biot (both BD Pharmingen) or Fibronectin (Abcam). CD31-Biot was revealed with a streptavidin-PE (BD Pharmingen) and fibronectin with a goat anti-rabbit-FITC (Invitrogen).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50740-fig1-v1.tif"/></fig><p>Thus, the existence or not of a mesenchymal transition determines a certain architecture of the tumor. Importantly, this structural organization influences the distribution of monocytes/macrophages and T cells. Indeed, this immune infiltrate is concentrated in the stromal sheets when they exist, whereas it is more uniformly dispersed in the tumor mass after EMT (<xref ref-type="bibr" rid="bib131">Thoreau et al., 2015</xref>; <xref ref-type="bibr" rid="bib141">Weiss et al., 2017</xref>).</p><p>The use of tumor models that present an architecture of tumor islets separated by stromal sheets is of particular relevance for the following reason. M. Angelo and colleagues have recently shown that, in breast cancer, an enriched co-occurrence of immune populations defines a structured immune environment that is indicative of a good prognosis (<xref ref-type="bibr" rid="bib75">Keren et al., 2018</xref>). They have established an important correlation between a structure (the spatial distribution of immune cells in the tumor) and a function (the efficacy of the anti-tumoral immune response), without suggesting a causal explanation for this correlation. On the basis of the previous discussion, we propose that a well-developed, regular stroma surrounding a functional vascular tree provides an oxygenated space in which immune cells can be recruited. The different cell types gathered there may interact and are ready to respond to an external stimulation. Murine models show that such structures are not observed when tumor cells have gone through EMT. If such a structure is important in human primary carcinoma, one should be aware of the limits of murine models that do not present such an architecture.</p></sec><sec id="s5-3"><title>Growth rate</title><p>As already pointed out, the growth of a tumor is entirely dependent on its vascularization. Indeed, in the absence of angiogenesis, a tumor cannot grow beyond 1–3 mm in diameter (<xref ref-type="bibr" rid="bib62">Greene, 1941</xref>; <xref ref-type="bibr" rid="bib60">Gimbrone et al., 1969</xref>). Once vascularized, the tumor cells that proliferate most actively are those located close to blood vessels (<xref ref-type="bibr" rid="bib128">Tannock, 1968</xref>). The growth rate of tumor cells is thus indirectly controlled by that of endothelial cells within the tumor (<xref ref-type="bibr" rid="bib129">Tannock, 1970</xref>).</p><p>Tumor growth rate <italic>diminishes</italic> when tumors outgrow their blood supply (<xref ref-type="bibr" rid="bib20">Cataland et al., 1962</xref>). Small TP tumors are better vascularized than large ones, in terms of average distance between blood vessels and tumor cells. Indeed, it has been shown that oxygen diffuses with a space constant of a few tens of microns. As a result, tumor cells that are located further than 60–80 µm from a blood vessel suffer from excessive hypoxia, which triggers their apoptosis followed by secondary necrosis (<xref ref-type="bibr" rid="bib130">Thomlinson and Gray, 1955</xref>; <xref ref-type="bibr" rid="bib17">Carmona-Fontaine et al., 2017</xref>) (and our own unpublished observations). This partially explains why the growth of TP tumors slows down when tumors are &gt; 1 g (or 1 cm<sup>3</sup>) (<xref ref-type="bibr" rid="bib20">Cataland et al., 1962</xref>) and <xref ref-type="fig" rid="fig2">Figure 2A</xref>. There are examples in which the growth rate is higher for TP than for SP tumors (<xref ref-type="bibr" rid="bib143">Wexler et al., 1965</xref>; <xref ref-type="bibr" rid="bib90">McCredie et al., 1971</xref>), but, given the limited number of available comparisons and inconsistent evidence this certainly cannot be considered to be a general rule (<xref ref-type="bibr" rid="bib108">Rous, 1914</xref>; <xref ref-type="bibr" rid="bib15">Burton and Begg, 1961</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Growth rate of TP and SP PyMT tumors.</title><p>(<bold>A</bold>) The growth of TP tumors slows down with time. (<bold>B</bold>) The growth of SP tumors, which is initially slow, accelerates with time. Data from 45 tumors from 45 TP mice and 26 tumors from 9 SP mice. The small and large tumor diameters, d and D, were measured with calipers. Tumor volume was approximated by the volume of a spheroid (d<sup>2</sup>.D/2). For each tumor, the volume at time day x is expressed relative to its volume at day 0, when the tumor volume was ~ 50–150 mm<sup>3</sup>. The ratios (volume(dx)/volume(d0)) expressed on a Log2 scale, are represented as a function of time.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50740-fig2-v1.tif"/></fig><p>Surprisingly, it is also possible, under some conditions, to observe an <italic>acceleration of tumor growth</italic>. Thus, we have observed that SP mammalian tumors have an initial slow growth rate, which increases about two-fold when tumors reach a size of around 6 mm in diameter (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), reaching a growth rate comparable to that of TP tumors. The reason for this frequent acceleration of SP tumor growth is unclear. One possibility is that tumor cell proliferation is initially slowed down by different microenvironmental brakes, including TGFβ, which is abundant in these tumors (<xref ref-type="bibr" rid="bib64">Guerin et al., 2019</xref>). At some point, tumor cells may become unresponsive to TGFβ, as shown in different tumor models (<xref ref-type="bibr" rid="bib64">Guerin et al., 2019</xref>).</p><p>Other examples of accelerations of tumor growth have been reported. For instance, when the size of SP tumors is reduced by surgery, the remaining part of the tumor regrows very rapidly, faster than before surgery (<xref ref-type="bibr" rid="bib67">Havas and Donnelly, 1961</xref>). This observation is also common for human tumors: a partial tumor regression in response to a treatment is followed by a swift regrowth.</p><p>Thus, variations in the rate of tumor growth may be observed in two directions: accelerations of tumor growth for some SP tumors, either spontaneously or after treatment, or a slowdown that may be attributed to an insufficient vasculature, and ensuing hypoxia and necrosis. With exactly the same tumor cells, we have observed either an acceleration in a SP context (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) or a slowing down in a TP context (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Such rate changes in tumor growth, combined with the inherent stochasticity involved in tumor formation mentioned earlier, cause important variability in tumor growth rates in murine models.</p><p>Altogether, tumor growth rate is strongly dependent on the angiogenesis rate. Tumors that grow fast are not only more aggressive but also more susceptible to antitumoral treatment for several reasons. First their vascular network is more immature and therefore more fragile. Second, rapidly proliferating cells are more susceptible to anti-mitotic drugs or to high local concentrations of IFNα (<xref ref-type="bibr" rid="bib123">Sujobert and Trautmann, 2016</xref>; <xref ref-type="bibr" rid="bib141">Weiss et al., 2017</xref>). To conclude on the rate of tumor growth: when tumor cells divide regularly, the tumor growth is exponential and linear on a log scale. However, this growth rate may be either accelerated, when the tumor escapes microenvironmental brakes (particularly conspicuous for SP tumors), or reduced, when angiogenesis becomes insufficient and hypoxic or necrotic regions appear.</p></sec><sec id="s5-4"><title>Tumor metabolism</title><p>Intense efforts have been devoted in the past century to answering the question of whether tumorigenesis could be a consequence of a peculiar metabolism, initially described by Otto Warburg. This important issue is mentioned only briefly here, given that no striking difference has been observed in the metabolism of TP versus SP tumors. However, it is worth underlining the mechanisms by which the metabolism of tumor cells and macrophages are linked to the vascular architecture and the spatial distribution of immune cells within the tumor.</p><p>Let us remind ourselves that the intense glycolytic metabolism in tumor cells discovered by Otto Warburg (<xref ref-type="bibr" rid="bib137">Warburg et al., 1927</xref>) is a way for these cells to use glycolysis not only to make ATP (with a low efficacy) but also to produce building blocks necessary for the synthesis of proteins, lipids and nucleotides (<xref ref-type="bibr" rid="bib134">Vander Heiden et al., 2009</xref>). As a by-product, they release lactate and acidify their immediate microenvironment. These phenomena contribute to organize the distribution of immune cells, in particular of the most abundant ones, macrophages. At the center of tumor islets, hypoxia, lactate and pH acidification are very high. This combination is toxic for macrophages, which prefer the more favorable microenvironment of stromal regions, close to blood vessels, where these toxic cues are minimized (<xref ref-type="bibr" rid="bib16">Carmona-Fontaine et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Carmona-Fontaine et al., 2017</xref>). Thus, the intratumoral localization of immune cells is strongly influenced by the global architecture of the tumor, which is itself the result of complex phenomena including gene networks dynamics, self-organization and stochastic events, as mentioned earlier.</p><p>In vitro experiments in which macrophages are co-cultured with tumor cells show that the Warburg metabolism is somehow contagious, because macrophages co-cultured in vitro with tumor cells also become more glycolytic (<xref ref-type="bibr" rid="bib100">Penny et al., 2016</xref>). The molecular basis of this contagion is still unclear. One may hypothesize that it involves tumor-derived lactic acid, which also influences the phenotype of tumor-associated macrophages (TAM). Indeed, in the presence of tumor-derived lactate, TAM become more prone to secrete VEGF in a HIF-1α-dependent way and to express arginase 1 (<xref ref-type="bibr" rid="bib27">Colegio et al., 2014</xref>).</p><p>Thus, the interrelated metabolism of tumor cells and macrophages contributes to the coupling between the vascular architecture and the localization of infiltrating immune cells within the tumor.</p></sec><sec id="s5-5"><title>Immune infiltrate and inflammation</title><p>As pointed out above, the <italic>localization</italic> of the immune tumor infiltrate is tightly linked to the vascular architecture. However, <italic>the nature and the properties</italic> of the immune infiltrating cells are a different issue, which will be examined now.</p><p>SP and TP tumors also differ in terms of the infiltration of TAM, usually the most abundant intratumoral immune cells. The renewal of TAMs is the result of an influx of monocytes followed by their ability to proliferate and differentiate (<xref ref-type="bibr" rid="bib54">Franklin et al., 2014</xref>). In TP tumors, the rate of monocyte influx is very high, as the half time for intratumoral monocyte influx following adoptive transfer of fluorescent monocytes is in the order of one day (<xref ref-type="bibr" rid="bib121">Strachan et al., 2013</xref>; <xref ref-type="bibr" rid="bib88">Ma et al., 2014</xref>). On the basis of the supplemental data from a study performed in the MMTV-PyMT model, the monocyte influx rate can be estimated to be roughly five times slower in a SP tumor than in a TP tumor (<xref ref-type="bibr" rid="bib54">Franklin et al., 2014</xref>). The inflammatory context of TP tumors is likely to account for the artificially accelerated influx of monocytes into these tumors. The differentiation of monocytes in TAMs may also be different in TP and SP tumors: MHCII<sup>+</sup>-activated TAM are more abundant in TP than in SP tumors (<xref ref-type="bibr" rid="bib64">Guerin et al., 2019</xref>), possibly because of a larger amount of TGFβ in SP tumors, as will be discussed later.</p><p>In both TP and SP tumors, only activated TAMs may exert an anti-tumoral function, but with different efficacy in the two models. For instance, the TAM-dependent anti-tumoral action of STING agonists can only be observed in TP tumors (see below). This is also true for the anti-tumoral effect of IL-12 (<xref ref-type="box" rid="box3">Box 3</xref>).</p><p>In murine SP models, except in their inducible version, the simultaneous development of the immune system and of the tumor leads to immune tolerance (<xref ref-type="bibr" rid="bib4">Anders et al., 2017</xref>). T cells in mice bearing SP tumors are tolerant or anergic, and thus, even after stimulation, unable to exert a strong anti-tumoral activity (<xref ref-type="bibr" rid="bib106">Reilly et al., 2000</xref>).</p><boxed-text id="box3"><label>Box 3.</label><caption><p>Different anti-tumoral actions of IL-12.</p></caption><p>The anti-tumoral action of IL-12 is frequently associated with type 1 T cell responses (<xref ref-type="bibr" rid="bib140">Weiss et al., 2007</xref>). However, IL-12 also contributes to polarize TAM towards an inflammatory, potentially anti-tumoral phenotype (<xref ref-type="bibr" rid="bib138">Watkins et al., 2007</xref>). This may explain why the anti-tumoral effect of IL-12 is maintained against tumors grafted in <italic>nude</italic> mice. In particular, IL-12 secretion by intratumoral myeloid cells may exert a strong anti-angiogenic activity. Indeed, repeated intraperitoneal injections of IL-12 affects the vascular network, enough to slow down the growth of TP tumors. Again, this is true for TP but not for SP tumors (<xref ref-type="bibr" rid="bib83">Lee et al., 2002</xref>).</p></boxed-text><p>Some SP tumors are characterized by the abundance of immunosuppressive <italic>myeloid-derived suppressor cells</italic> (MDSCs) (<xref ref-type="bibr" rid="bib113">Sevko et al., 2013</xref>; <xref ref-type="bibr" rid="bib26">Coffelt and de Visser, 2015</xref>), amongst which neutrophils often play an important pro-tumoral role, both in primary tumors (<xref ref-type="bibr" rid="bib36">Di Mitri et al., 2014</xref>; <xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>) and in metastases (<xref ref-type="bibr" rid="bib26">Coffelt and de Visser, 2015</xref>). Their presence may explain why an anti-tumoral effect may be obtained after adoptive transfer of antigen-specific T cells in mice bearing TP, but not SP, tumors (<xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>). The fact that non-stimulated neutrophils are immunosuppressive does not preclude the possibility that properly activated neutrophils may contribute to an anti-tumoral action (<xref ref-type="bibr" rid="bib35">Di Carlo et al., 2001</xref>; <xref ref-type="bibr" rid="bib141">Weiss et al., 2017</xref>). An immunosuppressive action may also be exerted by cancer-associated fibroblasts expressing fibroblast activation protein-α. This immunosuppression is at work both in TP (<xref ref-type="bibr" rid="bib78">Kraman et al., 2010</xref>) and in SP tumors (<xref ref-type="bibr" rid="bib45">Feig et al., 2013</xref>).</p><p>Inoculation with cancer cells results in massive tumor cell necrosis and in the release of tumor antigens from TP tumors that are able to trigger acute adaptive immune responses, whereas SP tumors frequently trigger chronic innate immune responses that preclude any acute T cell priming (<xref ref-type="bibr" rid="bib25">Ciampricotti et al., 2012</xref>). It is possible to immunize a mouse against a TP tumor, but usually not against a SP tumor. This is true if the immunization is specific, that is, performed with identical tumor cells (<xref ref-type="bibr" rid="bib69">Hirsch, 1962</xref>; <xref ref-type="bibr" rid="bib40">Ercolini et al., 2003</xref>), with tumor-specific antigens, or following a non-specific stimulation of the immune system, for instance with Bacillus Calmette–Guérin (<xref ref-type="bibr" rid="bib96">Old et al., 1961</xref>).</p><p><italic>Immunogenic cell death</italic> (ICD) is a concept that describes the following chain of events triggered by chemotherapy. Some chemotherapeutic drugs, such as doxorubicin, not only kill tumor cells and thus release tumor antigens but also elicit the appearance of a set of danger signals including ATP, HMGB1 or calreticulin, which are released into the extracellular space or exposed at the surface of dying cells (<xref ref-type="bibr" rid="bib57">Galluzzi et al., 2017</xref>). The combination of these events allows the triggering of a chemotherapy-induced immune response, which has been proposed to contribute to a large extent to the efficacy of doxorubicin. However, it is important to realize that the ICD concept, initially proposed by L. Zitvogel and G. Kroemer (<xref ref-type="bibr" rid="bib18">Casares et al., 2005</xref>), has been developed in hundreds of publications on the basis of experiments that were all performed with TP tumors. The fact that it is almost impossible to elicit ICD in SP murine tumors is worrying when considering the use of this concept for human tumors (<xref ref-type="bibr" rid="bib25">Ciampricotti et al., 2012</xref>). The immunosuppression observed in SP tumors, which is possibly a result of the abundance of TGFβ in these tumors (see below), may explain why chemotherapy on its own is not enough to elicit antitumor immune responses in SP tumors (<xref ref-type="bibr" rid="bib26">Coffelt and de Visser, 2015</xref>). An additional weakness of the ICD concept is that, in most papers, ICD slows down tumor growth but does not induce tumor regression.</p><p>Nevertheless, the notion of ICD may be useful if it is considered in a wider sense. Indeed, if instead of relying on an ICD-based chemotherapy alone, immune cell stimulation and chemotherapy are combined, then it could be expected that the immune response may be amplified by chemotherapy-induced ICD.</p></sec><sec id="s5-6"><title>TGFβ</title><p>The last factor examined in this review, which is key to understanding differences between TP and SP tumors, is TGFβ.</p><p>The abundance of TGFβ in tumors is quite variable. TGFβ may be produced by tumor cells (<xref ref-type="bibr" rid="bib110">Schlingensiepen et al., 2008</xref>) (and our unpublished data), by cancer-associated fibroblasts (<xref ref-type="bibr" rid="bib94">Nazareth et al., 2007</xref>), by dying cells (<xref ref-type="bibr" rid="bib23">Chen et al., 2001</xref>; <xref ref-type="bibr" rid="bib92">Moustakas et al., 2002</xref>), and by TAM (<xref ref-type="bibr" rid="bib11">Bonde et al., 2012</xref>). Of note, the secretion of TGFβ by macrophages increases after ingestion of dying cells (<xref ref-type="bibr" rid="bib42">Fadok et al., 1998</xref>). In benign tumors or at the pretumoral state, TGFβ, together with Notch (<xref ref-type="box" rid="box4">Box 4</xref>), exerts an anti-tumoral role (<xref ref-type="bibr" rid="bib30">Cui et al., 1994</xref>; <xref ref-type="bibr" rid="bib103">Pu et al., 2009</xref>), which should not be forgotten.</p><boxed-text id="box4"><label>Box 4.</label><caption><p>Anti-tumoral action of TGFβ and Notch.</p></caption><p>The pro-quiescence function of TGFβ may be exerted together with Notch function at the interface between tumor cells and macrophages. In a study performed in a SP murine mammary tumor model (<xref ref-type="bibr" rid="bib116">Shen et al., 2017</xref>), it has been shown that Notch may upregulate TGFβRI and thus sensitize cells to TGFβ. Conversely, TGFβ promotes the expression of JAG1, a Notch ligand, and Notch receptor activation, resulting in the production of IL-1β and CCL2 and in the recruitment of monocytes.</p></boxed-text><p>TGFβ is also necessary for the generation and maintenance of memory T cells (<xref ref-type="bibr" rid="bib109">Sanjabi et al., 2009</xref>; <xref ref-type="bibr" rid="bib19">Casey et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Hirai et al., 2019</xref>). After an initial anti-tumoral effect of TGFβ, the dominant effect becomes protumoral through different mechanisms. One mechanism is an immunosuppression, resulting from an inhibition of activated T cells by regulatory T cells and from the anti-proliferative action of TGFβ on T cells (<xref ref-type="bibr" rid="bib43">Fahlén et al., 2005</xref>; <xref ref-type="bibr" rid="bib41">Esquerré et al., 2008</xref>). In addition, TGFβ activates cancer-associated fibroblasts, which contribute to neoangiogenesis, and other responses associated with wound healing (<xref ref-type="bibr" rid="bib79">Kuperwasser et al., 2004</xref>). TGFβ is also a major inducer of EMT. Another mechanism is the acquisition by tumor cells of a resistance to TGFβ and to its anti-proliferative effects. Such a resistance may be due to an antagonism exerted by active Ras on TGFβ signaling (<xref ref-type="bibr" rid="bib43">Fahlén et al., 2005</xref>; <xref ref-type="bibr" rid="bib14">Burch et al., 2011</xref>).</p><p>Thus, TGFβ is a real conductor of the immunosuppressive orchestra. We have recently unraveled the existence of a new and major immunosuppressive effect of TGFβ. In the MMTV-PyMT model, despite important similarities (<xref ref-type="bibr" rid="bib135">Varticovski et al., 2007</xref>), there is a major difference between orthotopic TP and SP tumors. Indeed, in this model, TGFβ is found in abundance and is able to block IFNβ-dependent responses in SP tumors, but not in TP tumors. In this phenomenon, TAM plays key roles, as a source and a target of both IFNβ/α and TGFβ. The TGFβ-dependent inhibition of IFNβ/α signaling may explain why SP tumors are resistant to the STING agonist DMXAA, which can trigger the regression of TP but not of SP tumors, unless mice bearing SP tumors are also treated with an anti-TGFβ antibody (<xref ref-type="bibr" rid="bib64">Guerin et al., 2019</xref>).</p><p>The abundance of TGFβ is observed not only in classical murine SP models, but also in tumor-bearing mice in the sporadic tumor model, even though its involvement in the development of tumors in the sporadic tumor model has not been established (<xref ref-type="bibr" rid="bib145">Willimsky and Blankenstein, 2007</xref>). In human tumors, the abundance of TGFβ has been associated with a bad prognosis (<xref ref-type="bibr" rid="bib61">Gold, 1999</xref>; <xref ref-type="bibr" rid="bib12">Bruna et al., 2007</xref>). TGFβ mRNA is most abundant in head and neck cancers (<ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/ENSG00000105329-TGFB1/pathology">https://www.proteinatlas.org/ENSG00000105329-TGFB1/pathology</ext-link>). The next three cancers with abundant TGFβ are kidney, stomach and pancreatic cancers. For all of these cancers except pancreatic cancer, the patient prognosis is much worse for the group of patients with the highest intratumoral TGFβ level. As there is an increasing number of cancer treatments in which IFNα is at play (see e.g. <xref ref-type="bibr" rid="bib119">Sistigu et al., 2014</xref> for example), TGFβ-dependent inhibition of IFNβ/α signaling is likely to be involved in numerous treatment-resistance phenomena. As previously reported (<xref ref-type="bibr" rid="bib64">Guerin et al., 2019</xref>), it would thus be of major interest to think of combining such treatments with TGFβ blockade.</p><p>However, this mechanism cannot always explain the differential sensitivity of TP and SP tumors to anti-tumoral treatments. Indeed, when comparing TiRP (<xref ref-type="bibr" rid="bib72">Huijbers et al., 2006</xref>; <xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>), a SP model of melanoma, and T429 tumors, its TP counterpart, one can observe that DMXAA is active against TP melanomas and not against SP melanomas (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In this case, SP tumors also express higher levels of TGFβ than TP tumors (<xref ref-type="bibr" rid="bib46">Fenton et al., 2001</xref>). However, contrary to what was observed in PyMT tumors, DMXAA seems to induce equal levels of IFNα signaling in both SP and TP tumors. The different sensitivity of SP and TP melanomas to DMXAA therefore relies on a different mechanism. We have mentioned above that another anti-tumoral treatment, that is the adoptive transfer of anti-tumoral-specific T cells, was active against the TP melanoma but not the SP melanoma. This differential sensitivity appears to be due to the larger abundance of MDSCs in the SP melanoma (<xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>). These MDSC mediate immunosuppression by triggering the apoptosis of tumor-infiltrating CD8 T cells through the Fas/Fas-ligand pathway (<xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>). Whether or not the differential response to DMXAA is also MDSC-dependent remains to be clarified.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>DMXAA induces a transient regression of TP melanomas but not of isogenic SP tumors.</title><p>(<bold>A</bold>) B10.D2 mice were injected subcutaneously with 2 million T429.11 cells, a cell line derived from an induced Amela TiRP tumor (<xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>) (TP tumors). (<bold>B</bold>) TiRP mice were treated subcutaneously with 2 mg of 4-OH tamoxifen to induce tumor development as described in <xref ref-type="bibr" rid="bib150">Zhu et al. (2017)</xref> (SP tumors). Tumor growth was measured with calipers and approximated to the volume of a spheroid (d<sup>2</sup>.D/2). When the average diameter was between 7 and 9 mm, T429-tumor-bearing mice or TiRP-tumor-bearing mice were randomized into two groups, with an average tumor volume of 220 mm<sup>3</sup>, and were treated with a single intraperitoneal (i.p.) injection of DMXAA (23 mg/kg) or DMSO (day 0). Tumor growth was monitored. Graphs show means ± S.E.M.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50740-fig3-v1.tif"/></fig><p>A third example of identical tumor cells that behave differently in a SP and a TP context are represented by the <italic>Kras<sup>G12D/+</sup></italic>;<italic>Trp53<sup>R172H/+</sup></italic>;<italic>Pdx-1-Cre</italic> (KPC) mice, which develop spontaneous pancreatic ductal adenocarcinoma (PDAC), and the KPC-derived PDAC cell line. There too, treatment of mice with a chemotherapy plus an anti-CD40 antibody results in a conspicuous T cell infiltrate in TP but not in SP KPC tumors (<xref ref-type="bibr" rid="bib7">Beatty et al., 2015</xref>). The reason for this difference has not been elucidated.</p></sec></sec><sec id="s6"><title>Organ-specificity of tumors</title><p>It is often considered that different organs give rise to different types of human cancers that have distinct genomic profiles and sensitivities to anticancer therapies. The origin of these differences has been explored with different approaches including: (i) profiling the tumor-associated mutations and the transcriptional landscape of the immune infiltrate; and (ii) considering the original functioning of the healthy organ and the cross-talk between tumor cells and the stromal and immune microenvironment. Here, we examine factors that could be decisive for the organ-specificity of human tumors, and consider which preclinical tumor models should be used to take this specificity into account.</p><sec id="s6-1"><title>High-throughput analyses</title><p>To what extent can sets of mutations in tumors be viewed as organ-specific? A few mutations are found more frequently in some organs than in others. For instance, ∼50% of melanomas harbor recurrent BRAF mutations, which are key to the immune evasion of melanoma (<xref ref-type="bibr" rid="bib124">Sumimoto et al., 2006</xref>) and which are amenable to specific treatments (<xref ref-type="bibr" rid="bib107">Robert et al., 2015</xref>), whereas such mutations are much less frequent in colon cancers (<xref ref-type="bibr" rid="bib29">Corcoran et al., 2012</xref>). By contrast, colorectal cancers frequently harbor KRAS mutations, which are rare in melanomas (<xref ref-type="bibr" rid="bib1">AACR Project GENIE Consortium, 2017</xref>) but extremely frequent in pancreatic cancers (<xref ref-type="bibr" rid="bib80">Lanfredini et al., 2019</xref>). A thorough analysis of the mutanome of &gt;60,000 tumors has demonstrated, however, that <italic>tumors have remarkably few shared alterations with other tumors, even in the context of major driver alterations and in specific disease types</italic> (<xref ref-type="bibr" rid="bib66">Hartmaier et al., 2017</xref>). Thus, mutanome profiles are too variable and overlapping to constitute major determinants of the organ-specificity of tumors.</p><p>What about the global mutational burden? It is usually considered that a higher mutational load means that a tumor will produce a larger number of neoantigens, leading to a higher immunogenicity of the tumor. The average mutational burden, or number of neoantigens, is approximately 10 times higher in melanoma or lung squamous carcinoma than in bone cancer, germ cell tumors or thyroid cancer (<xref ref-type="bibr" rid="bib2">Alexandrov et al., 2013</xref>; <xref ref-type="bibr" rid="bib112">Schumacher and Schreiber, 2015</xref>; <xref ref-type="bibr" rid="bib1">AACR Project GENIE Consortium, 2017</xref>). Overall, highly mutated tumors do indeed have a better respone rate to immunotherapeutics (<xref ref-type="bibr" rid="bib71">Hugo et al., 2016</xref>). However, there is also a substantial number of patients who have a good immune response despite a low mutational load, and vice versa (<xref ref-type="bibr" rid="bib142">Wellenstein and de Visser, 2018</xref>). What appears to be decisive for the efficacy of checkpoint inhibitors is the pre-existing immune context, including T cell infiltrate and the presence of immune-costimulatory molecules (<xref ref-type="bibr" rid="bib132">Tumeh et al., 2014</xref>; <xref ref-type="bibr" rid="bib5">Auslander et al., 2018</xref>), which is often but not necessarily related to the mutational burden.</p><p>Are there immune profiles that are specific to tumors in a given organ? This appears as an interesting hypothesis, since both the anatomic location and the functions of an organ constrain the type of pathogen that may invade them, and therefore how the immune system has evolved to adapt host defense accordingly. In particular, the abundance of the different types of resident immune cells is quite variable from organ to organ in healthy tissues. However, the variability in the abundance of immune cells observed amongst, say, lung tumors is much larger than that observed in the immune profile of healthy lungs (<xref ref-type="bibr" rid="bib99">Pao et al., 2018</xref>). Because of this tumor-to-tumor variability for a given organ, and even though there is a definite influence of an organ on its immune infiltrate in healthy conditions, one cannot say that one tumor immune profile is organ-specific.</p><p>Thus, these approaches have provided a huge amount of data on many tumor types. However, <italic>owing to the descriptive nature of these analyses, these studies do not yield mechanistic insights</italic> and they have not led to strong predictive conclusions on tumor-specific treatments (<xref ref-type="bibr" rid="bib142">Wellenstein and de Visser, 2018</xref>).</p></sec><sec id="s6-2"><title>Functional points of view</title><p>One may wonder if there is a functional explanation behind the fact that the average mutational burden is much higher in melanoma or lung squamous carcinoma than in thyroid or bone cancer. We propose here such an explanation. It is now clear that several key mutations are necessary but not sufficient for a tumor to develop. Tumor development also requires a favorable, tumor-promoting microenvironment, as thoughtfully predicted in the ‘<italic>seed and soil</italic>’ theory of S. Paget in 1889, a theory often revisited since then (<xref ref-type="bibr" rid="bib49">Fidler, 2003</xref>). A poly-mutated transformed cell is initially prevented from proliferating by a protective microenvironment that includes not only the immune system but also the normal stroma (<xref ref-type="bibr" rid="bib93">Mueller and Fusenig, 2004</xref>; <xref ref-type="bibr" rid="bib10">Bissell and Hines, 2011</xref>). One may hypothesize that tumors with the highest mutation load are those on which the initial anti-tumoral brake was the strongest, so that a large number of mutations were needed for the nascent tumor to escape from its anti-tumoral microenvironment. Thus, melanoma or lung carcinoma would appear in a context that is quite unfavorable for tumor development, whereas, at the other end of the mutational burden spectrum, bone cancer or germ cell tumors would emerge in a less constrained environment (<xref ref-type="bibr" rid="bib1">AACR Project GENIE Consortium, 2017</xref>). This could be related to the fact that both the skin and mucosa represent interfaces between the inside and outside of the organism, where both the exposure to pathogens or other insults and the immune surveillance against them are greatest.</p><p>In such a view, a mutational burden would be a measure of the efficacy of local immune surveillance rather than a decisive tumor cause in itself. The key determinant here would be the anatomical location of the organ and its associated functions and exposure to insults.</p><p>In the whole review, we have underlined the importance of structure–function relationships in the tumor microenvironment. It appears that this issue is probably also a key factor in the organ specificity of tumors. This is true for all the dimensions that we have taken into account: general architecture of the tumor, structure of the vascular tree, and stroma development, all of these elements influencing in turn the immune infiltrate. It is in this structure that a cellular network including tumor, stromal, immune and endothelial cells self-organizes, with the growth factors and inhibitors produced by some cells influencing the development of other ones. This network is likely to be organ-specific, because the dominant resident cells and growing factors are not the same in all organs.</p><p>To illustrate the relative importance of mutations or gene expression on one hand, and anatomical location and function on the other, one can observe that the frequency of mutated KRAS is high in colon cancer, and very high in pancreatic cancer. However, the very different prognosis for the two tumors underlines that a mutated KRAS cannot explain the very bad prognosis for pancreatic tumors. What is striking and specific in pancreatic tumors is an exuberant stroma, including specific fibroblasts (pancreatic stellate cells), amorphous fibers, plus a macrophage infiltrate, and an intense fibro-inflammatory response that generates a very high interstitial fluid pressure (<xref ref-type="bibr" rid="bib149">Zhang et al., 2018</xref>). In addition, pancreatic tumors show a particularly defective vascularization (<xref ref-type="bibr" rid="bib102">Provenzano et al., 2012</xref>), leading to hypoxia and its consequences. One may hypothesize that it is the combination of mutated KRAS with these organ-specific features (including organ-specific growth factors) that results in a particularly nasty cancer.</p><p>Which conclusions could then be drawn concerning optimal preclinical tumor models ? First, we have to recognize that we are unable, in murine models, to address properly an important issue: human tumors usually take years to start really growing, and this very long latency phase, during which mutations probably accumulate, is impossible to recapitulate in murine tumors that could be used conveniently in large numbers. Second, there is an organ specificity for tumors that is associated with the specificities of organs: anatomical location, functions, dominant cellular and molecular actors. Thus, when working on preclinical models for potential breast cancer treatments, it makes sense to use either spontaneous mammary tumors or dissociated mammary tumors transplanted orthotopically. By contrast, with the perspective of treating pancreatic cancer, a tumor cell line of pancreas or lung origin, implanted subcutaneously, will be of low relevance, especially if it is a post-EMT cell line that prevents the formation of a typical tumor structure with tumor islets and a conspicuous stroma. Nevertheless, many results, and some of them quite interesting, have been obtained with such imperfect approaches.</p></sec></sec><sec id="s7"><title>Conclusions</title><p>All animal models have advantages and drawbacks, none of them may be considered as ideal. However, authors have a marked propensity to mention the advantages of the model they use, and too often choose not to discuss its drawbacks. In this review, the strengths and weaknesses that are inherent to specific tumor models are analyzed.</p><p>Sporadic tumor models are certainly the closest to human tumors, but their slowness to develop and the large variability in their growth make them barely usable, in practice, for systematic studies.</p><p>SP mammary tumors arising in female C3H mice almost fall into the same category, but are somehow more simple to use, especially if the probability of tumor occurrence is increased by infecting the mice with MMTV (<xref ref-type="bibr" rid="bib48">Fenton et al., 2005</xref>).</p><p>GEMM, characterized by the expression of several oncogenes in a specific tissue, represent an interesting compromise. They keep proximity to human tumors, even though their growth rate is faster. They present important constraints of use, albeit less huge than for sporadic models.</p><p>TP tumors constitute the most popular tumor model. As pointed out throughout this review, they differ profoundly from tumors that grow spontaneously in humans or in SP murine models. The difference with SP tumors is larger for tumors growing after the injection of a cell line than for those formed after the injection of the various cells dissociated from a spontaneous tumor. The difference with SP tumors is also larger for tumors that are implanted subcutaneously rather than orthotopically. Another difference may be observed between tumors implanted subcutaneously or intradermally (<xref ref-type="bibr" rid="bib74">Joncker et al., 2016</xref>). The main ways in which TP and SP tumors differ are summarized below and in <xref ref-type="table" rid="table1">Table 1</xref>.</p><p>The vascularization of TP tumors is not dependent on an angiogenic switch, which has already taken place in implanted cells. Thereafter, the growth rate of the vascular network is usually faster in TP tumors than in SP tumors, contributing to the frequently faster growth rate of TP tumors. However, the rapid growth of the vascular tree of TP tumors makes it more immature and more fragile than that of SP tumors.</p><p>In TP tumors, potential anti-tumoral T cells differentiate without the tolerization phase that takes place in SP murine tumors and in human tumors. The myeloid infiltrate is more immunosuppressive in SP tumors for several reasons. One may be a larger abundance of neutrophil attractants, for reasons which remain to be determined (<xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>). Another reason may be a larger concentration in some SP tumors (<xref ref-type="bibr" rid="bib64">Guerin et al., 2019</xref>; <xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>) of TGFβ, which polarizes TAM towards a more immunosuppressive state.</p><p>These strong conclusions could be drawn because we have been able to compare, for two tumor types (mammary and melanoma), isogenic tumor cells in the context of both TP and SP tumors. The conclusions obtained from the two systems were not identical but were complementary. It would be of major interest to extend such a comparison to additional pairs of SP and TP tumors.</p><p>All of these features may contribute to explain the different sensitivity of TP and SP murine tumors to a large spectrum of anti-tumoral treatments, which work better (and sometimes only) in TP tumors (<xref ref-type="table" rid="table1">Table 1</xref>). This is the case for the anti-tumoral effect of cortisone (<xref ref-type="bibr" rid="bib15">Burton and Begg, 1961</xref>), the efficiency of the adoptive cell transfer of antigen-specific T cells (<xref ref-type="bibr" rid="bib150">Zhu et al., 2017</xref>), practically all the ICD-based chemotherapies, and the anti-angiogenic effects of IL-12 (<xref ref-type="bibr" rid="bib83">Lee et al., 2002</xref>) or DMXAA.</p><p>Erroneous conclusions may be drawn from studies with TP tumors. For instance, tumors growing after implantation of B16 melanoma lines, or of LLC or MAD109 lung tumor cell lines, are poorly immunogenic and resistant to immunotherapy, in contrast to the responses observed in the corresponding tumors in patients (<xref ref-type="bibr" rid="bib148">Zeiser et al., 2012</xref>). These observations do not imply that transplanted murine tumor models should no longer be used, but they indicate that data translation from these models to human studies without an intermediate validation in SP models may be risky. Although this seems to be an elementary caution, it has not always been taken, for instance, for the phase III clinal trial with DMXAA (<xref ref-type="bibr" rid="bib81">Lara et al., 2011</xref>). We have also pointed out that, in many cases, human xenografts appear to be a false good idea, because they represent a situation in which the multiple interactions between tumor cells, T cells, macrophages, stromal cells and endothelial cells cannot be properly reconstituted. Finally, in order to be able to use certain molecular tools, research has been more and more concentrated on a few strains of laboratory mice. It is reasonable to think that diversifying the animal models used in research would help to propose more efficient anti-tumoral treatments.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by Worldwide Cancer Research (UK) (grant AICR # 13–0260), the ‘Comité de Paris de La Ligue Contre le Cancer’, CNRS, INSERM and University Paris-Descartes. MG was supported by the Ministère de l’Education Nationale, de l’Enseignement Supérieur et de la Recherche (France). VF was supported by FNRS (Belgium), application # 28095636.</p></ack><sec id="s8" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>AACR Project GENIE Consortium</collab></person-group><year iso-8601-date="2017">2017</year><article-title>AACR project GENIE: powering precision medicine through an international consortium</article-title><source>Cancer Discovery</source><volume>7</volume><fpage>818</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0151</pub-id><pub-id pub-id-type="pmid">28572459</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Aparicio</surname> <given-names>SA</given-names></name><name><surname>Behjati</surname> <given-names>S</given-names></name><name><surname>Biankin</surname> <given-names>AV</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>Bolli</surname> <given-names>N</given-names></name><name><surname>Borg</surname> <given-names>A</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Boyault</surname> <given-names>S</given-names></name><name><surname>Burkhardt</surname> <given-names>B</given-names></name><name><surname>Butler</surname> <given-names>AP</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Davies</surname> <given-names>HR</given-names></name><name><surname>Desmedt</surname> <given-names>C</given-names></name><name><surname>Eils</surname> <given-names>R</given-names></name><name><surname>Eyfjörd</surname> <given-names>JE</given-names></name><name><surname>Foekens</surname> <given-names>JA</given-names></name><name><surname>Greaves</surname> <given-names>M</given-names></name><name><surname>Hosoda</surname> <given-names>F</given-names></name><name><surname>Hutter</surname> <given-names>B</given-names></name><name><surname>Ilicic</surname> <given-names>T</given-names></name><name><surname>Imbeaud</surname> <given-names>S</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Imielinsk</surname> <given-names>M</given-names></name><name><surname>Jäger</surname> <given-names>N</given-names></name><name><surname>Jones</surname> <given-names>DT</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Knappskog</surname> <given-names>S</given-names></name><name><surname>Kool</surname> <given-names>M</given-names></name><name><surname>Lakhani</surname> <given-names>SR</given-names></name><name><surname>López-Otín</surname> <given-names>C</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Munshi</surname> <given-names>NC</given-names></name><name><surname>Nakamura</surname> <given-names>H</given-names></name><name><surname>Northcott</surname> <given-names>PA</given-names></name><name><surname>Pajic</surname> <given-names>M</given-names></name><name><surname>Papaemmanuil</surname> <given-names>E</given-names></name><name><surname>Paradiso</surname> <given-names>A</given-names></name><name><surname>Pearson</surname> <given-names>JV</given-names></name><name><surname>Puente</surname> <given-names>XS</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Ramakrishna</surname> <given-names>M</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Richter</surname> <given-names>J</given-names></name><name><surname>Rosenstiel</surname> <given-names>P</given-names></name><name><surname>Schlesner</surname> <given-names>M</given-names></name><name><surname>Schumacher</surname> <given-names>TN</given-names></name><name><surname>Span</surname> <given-names>PN</given-names></name><name><surname>Teague</surname> <given-names>JW</given-names></name><name><surname>Totoki</surname> <given-names>Y</given-names></name><name><surname>Tutt</surname> <given-names>AN</given-names></name><name><surname>Valdés-Mas</surname> <given-names>R</given-names></name><name><surname>van Buuren</surname> <given-names>MM</given-names></name><name><surname>van 't Veer</surname> <given-names>L</given-names></name><name><surname>Vincent-Salomon</surname> <given-names>A</given-names></name><name><surname>Waddell</surname> <given-names>N</given-names></name><name><surname>Yates</surname> <given-names>LR</given-names></name><name><surname>Zucman-Rossi</surname> <given-names>J</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Lichter</surname> <given-names>P</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Grimmond</surname> <given-names>SM</given-names></name><name><surname>Siebert</surname> <given-names>R</given-names></name><name><surname>Campo</surname> <given-names>E</given-names></name><name><surname>Shibata</surname> <given-names>T</given-names></name><name><surname>Pfister</surname> <given-names>SM</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><collab>Australian Pancreatic Cancer Genome Initiative</collab><collab>ICGC Breast Cancer Consortium</collab><collab>ICGC MMML-Seq Consortium</collab><collab>ICGC PedBrain</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Signatures of mutational processes in human Cancer</article-title><source>Nature</source><volume>500</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nature12477</pub-id><pub-id pub-id-type="pmid">23945592</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allard</surname> <given-names>B</given-names></name><name><surname>Pommey</surname> <given-names>S</given-names></name><name><surname>Smyth</surname> <given-names>MJ</given-names></name><name><surname>Stagg</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs</article-title><source>Clinical Cancer Research</source><volume>19</volume><fpage>5626</fpage><lpage>5635</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0545</pub-id><pub-id pub-id-type="pmid">23983257</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname> <given-names>K</given-names></name><name><surname>Kershaw</surname> <given-names>O</given-names></name><name><surname>Larue</surname> <given-names>L</given-names></name><name><surname>Gruber</surname> <given-names>AD</given-names></name><name><surname>Blankenstein</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapy</article-title><source>International Journal of Cancer</source><volume>141</volume><fpage>2551</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.1002/ijc.31009</pub-id><pub-id pub-id-type="pmid">28833076</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auslander</surname> <given-names>N</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Lee</surname> <given-names>JS</given-names></name><name><surname>Frederick</surname> <given-names>DT</given-names></name><name><surname>Miao</surname> <given-names>B</given-names></name><name><surname>Moll</surname> <given-names>T</given-names></name><name><surname>Tian</surname> <given-names>T</given-names></name><name><surname>Wei</surname> <given-names>Z</given-names></name><name><surname>Madan</surname> <given-names>S</given-names></name><name><surname>Sullivan</surname> <given-names>RJ</given-names></name><name><surname>Boland</surname> <given-names>G</given-names></name><name><surname>Flaherty</surname> <given-names>K</given-names></name><name><surname>Herlyn</surname> <given-names>M</given-names></name><name><surname>Ruppin</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1545</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0157-9</pub-id><pub-id pub-id-type="pmid">30127394</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bearss</surname> <given-names>DJ</given-names></name><name><surname>Subler</surname> <given-names>MA</given-names></name><name><surname>Hundley</surname> <given-names>JE</given-names></name><name><surname>Troyer</surname> <given-names>DA</given-names></name><name><surname>Salinas</surname> <given-names>RA</given-names></name><name><surname>Windle</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors</article-title><source>Oncogene</source><volume>19</volume><fpage>1114</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203275</pub-id><pub-id pub-id-type="pmid">10713698</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beatty</surname> <given-names>GL</given-names></name><name><surname>Winograd</surname> <given-names>R</given-names></name><name><surname>Evans</surname> <given-names>RA</given-names></name><name><surname>Long</surname> <given-names>KB</given-names></name><name><surname>Luque</surname> <given-names>SL</given-names></name><name><surname>Lee</surname> <given-names>JW</given-names></name><name><surname>Clendenin</surname> <given-names>C</given-names></name><name><surname>Gladney</surname> <given-names>WL</given-names></name><name><surname>Knoblock</surname> <given-names>DM</given-names></name><name><surname>Guirnalda</surname> <given-names>PD</given-names></name><name><surname>Vonderheide</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6Clow F4/80+ extratumoral macrophages</article-title><source>Gastroenterology</source><volume>149</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.04.010</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergers</surname> <given-names>G</given-names></name><name><surname>Javaherian</surname> <given-names>K</given-names></name><name><surname>Lo</surname> <given-names>KM</given-names></name><name><surname>Folkman</surname> <given-names>J</given-names></name><name><surname>Hanahan</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Effects of angiogenesis inhibitors on multistage carcinogenesis in mice</article-title><source>Science</source><volume>284</volume><fpage>808</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1126/science.284.5415.808</pub-id><pub-id pub-id-type="pmid">10221914</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergers</surname> <given-names>G</given-names></name><name><surname>Brekken</surname> <given-names>R</given-names></name><name><surname>McMahon</surname> <given-names>G</given-names></name><name><surname>Vu</surname> <given-names>TH</given-names></name><name><surname>Itoh</surname> <given-names>T</given-names></name><name><surname>Tamaki</surname> <given-names>K</given-names></name><name><surname>Tanzawa</surname> <given-names>K</given-names></name><name><surname>Thorpe</surname> <given-names>P</given-names></name><name><surname>Itohara</surname> <given-names>S</given-names></name><name><surname>Werb</surname> <given-names>Z</given-names></name><name><surname>Hanahan</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis</article-title><source>Nature Cell Biology</source><volume>2</volume><fpage>737</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1038/35036374</pub-id><pub-id pub-id-type="pmid">11025665</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bissell</surname> <given-names>MJ</given-names></name><name><surname>Hines</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Why don't we get more Cancer? A proposed role of the microenvironment in restraining Cancer progression</article-title><source>Nature Medicine</source><volume>17</volume><fpage>320</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1038/nm.2328</pub-id><pub-id pub-id-type="pmid">21383745</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonde</surname> <given-names>AK</given-names></name><name><surname>Tischler</surname> <given-names>V</given-names></name><name><surname>Kumar</surname> <given-names>S</given-names></name><name><surname>Soltermann</surname> <given-names>A</given-names></name><name><surname>Schwendener</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors</article-title><source>BMC Cancer</source><volume>12</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-12-35</pub-id><pub-id pub-id-type="pmid">22273460</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruna</surname> <given-names>A</given-names></name><name><surname>Darken</surname> <given-names>RS</given-names></name><name><surname>Rojo</surname> <given-names>F</given-names></name><name><surname>Ocaña</surname> <given-names>A</given-names></name><name><surname>Peñuelas</surname> <given-names>S</given-names></name><name><surname>Arias</surname> <given-names>A</given-names></name><name><surname>Paris</surname> <given-names>R</given-names></name><name><surname>Tortosa</surname> <given-names>A</given-names></name><name><surname>Mora</surname> <given-names>J</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Seoane</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene</article-title><source>Cancer Cell</source><volume>11</volume><fpage>147</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.11.023</pub-id><pub-id pub-id-type="pmid">17292826</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucala</surname> <given-names>R</given-names></name><name><surname>Spiegel</surname> <given-names>LA</given-names></name><name><surname>Chesney</surname> <given-names>J</given-names></name><name><surname>Hogan</surname> <given-names>M</given-names></name><name><surname>Cerami</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair</article-title><source>Molecular Medicine</source><volume>1</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/BF03403533</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burch</surname> <given-names>ML</given-names></name><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>Little</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Smad Linker region phosphorylation in the regulation of extracellular matrix synthesis</article-title><source>Cellular and Molecular Life Sciences</source><volume>68</volume><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/s00018-010-0514-4</pub-id><pub-id pub-id-type="pmid">20820849</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname> <given-names>AF</given-names></name><name><surname>Begg</surname> <given-names>RW</given-names></name></person-group><year iso-8601-date="1961">1961</year><article-title>Effect of cortisone on growth, DNA, RNA, and protein of spontaneous and transplanted mammary tumors in mice</article-title><source>Journal of the National Cancer Institute</source><volume>26</volume><fpage>601</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">13689276</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona-Fontaine</surname> <given-names>C</given-names></name><name><surname>Bucci</surname> <given-names>V</given-names></name><name><surname>Akkari</surname> <given-names>L</given-names></name><name><surname>Deforet</surname> <given-names>M</given-names></name><name><surname>Joyce</surname> <given-names>JA</given-names></name><name><surname>Xavier</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Emergence of spatial structure in the tumor microenvironment due to the warburg effect</article-title><source>PNAS</source><volume>110</volume><fpage>19402</fpage><lpage>19407</lpage><pub-id pub-id-type="doi">10.1073/pnas.1311939110</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona-Fontaine</surname> <given-names>C</given-names></name><name><surname>Deforet</surname> <given-names>M</given-names></name><name><surname>Akkari</surname> <given-names>L</given-names></name><name><surname>Thompson</surname> <given-names>CB</given-names></name><name><surname>Joyce</surname> <given-names>JA</given-names></name><name><surname>Xavier</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metabolic origins of spatial organization in the tumor microenvironment</article-title><source>PNAS</source><volume>114</volume><fpage>2934</fpage><lpage>2939</lpage><pub-id pub-id-type="doi">10.1073/pnas.1700600114</pub-id><pub-id pub-id-type="pmid">28246332</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casares</surname> <given-names>N</given-names></name><name><surname>Pequignot</surname> <given-names>MO</given-names></name><name><surname>Tesniere</surname> <given-names>A</given-names></name><name><surname>Ghiringhelli</surname> <given-names>F</given-names></name><name><surname>Roux</surname> <given-names>S</given-names></name><name><surname>Chaput</surname> <given-names>N</given-names></name><name><surname>Schmitt</surname> <given-names>E</given-names></name><name><surname>Hamai</surname> <given-names>A</given-names></name><name><surname>Hervas-Stubbs</surname> <given-names>S</given-names></name><name><surname>Obeid</surname> <given-names>M</given-names></name><name><surname>Coutant</surname> <given-names>F</given-names></name><name><surname>Métivier</surname> <given-names>D</given-names></name><name><surname>Pichard</surname> <given-names>E</given-names></name><name><surname>Aucouturier</surname> <given-names>P</given-names></name><name><surname>Pierron</surname> <given-names>G</given-names></name><name><surname>Garrido</surname> <given-names>C</given-names></name><name><surname>Zitvogel</surname> <given-names>L</given-names></name><name><surname>Kroemer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death</article-title><source>The Journal of Experimental Medicine</source><volume>202</volume><fpage>1691</fpage><lpage>1701</lpage><pub-id pub-id-type="doi">10.1084/jem.20050915</pub-id><pub-id pub-id-type="pmid">16365148</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casey</surname> <given-names>KA</given-names></name><name><surname>Fraser</surname> <given-names>KA</given-names></name><name><surname>Schenkel</surname> <given-names>JM</given-names></name><name><surname>Moran</surname> <given-names>A</given-names></name><name><surname>Abt</surname> <given-names>MC</given-names></name><name><surname>Beura</surname> <given-names>LK</given-names></name><name><surname>Lucas</surname> <given-names>PJ</given-names></name><name><surname>Artis</surname> <given-names>D</given-names></name><name><surname>Wherry</surname> <given-names>EJ</given-names></name><name><surname>Hogquist</surname> <given-names>K</given-names></name><name><surname>Vezys</surname> <given-names>V</given-names></name><name><surname>Masopust</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues</article-title><source>The Journal of Immunology</source><volume>188</volume><fpage>4866</fpage><lpage>4875</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200402</pub-id><pub-id pub-id-type="pmid">22504644</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cataland</surname> <given-names>S</given-names></name><name><surname>Cohen</surname> <given-names>C</given-names></name><name><surname>Sapirstein</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="1962">1962</year><article-title>Relationship between size and perfusion rate of transplanted tumors</article-title><source>Journal of the National Cancer Institute</source><volume>29</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">13877297</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname> <given-names>ZR</given-names></name><name><surname>Connelly</surname> <given-names>CF</given-names></name><name><surname>Fabrizio</surname> <given-names>D</given-names></name><name><surname>Gay</surname> <given-names>L</given-names></name><name><surname>Ali</surname> <given-names>SM</given-names></name><name><surname>Ennis</surname> <given-names>R</given-names></name><name><surname>Schrock</surname> <given-names>A</given-names></name><name><surname>Campbell</surname> <given-names>B</given-names></name><name><surname>Shlien</surname> <given-names>A</given-names></name><name><surname>Chmielecki</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>F</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Tabori</surname> <given-names>U</given-names></name><name><surname>Kennedy</surname> <given-names>M</given-names></name><name><surname>Lieber</surname> <given-names>DS</given-names></name><name><surname>Roels</surname> <given-names>S</given-names></name><name><surname>White</surname> <given-names>J</given-names></name><name><surname>Otto</surname> <given-names>GA</given-names></name><name><surname>Ross</surname> <given-names>JS</given-names></name><name><surname>Garraway</surname> <given-names>L</given-names></name><name><surname>Miller</surname> <given-names>VA</given-names></name><name><surname>Stephens</surname> <given-names>PJ</given-names></name><name><surname>Frampton</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Analysis of 100,000 human Cancer genomes reveals the landscape of tumor mutational burden</article-title><source>Genome Medicine</source><volume>9</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-017-0424-2</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>TA</given-names></name><name><surname>Yarchoan</surname> <given-names>M</given-names></name><name><surname>Jaffee</surname> <given-names>E</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name><name><surname>Quezada</surname> <given-names>SA</given-names></name><name><surname>Stenzinger</surname> <given-names>A</given-names></name><name><surname>Peters</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic</article-title><source>Annals of Oncology</source><volume>30</volume><fpage>44</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy495</pub-id><pub-id pub-id-type="pmid">30395155</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Frank</surname> <given-names>ME</given-names></name><name><surname>Jin</surname> <given-names>W</given-names></name><name><surname>Wahl</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu</article-title><source>Immunity</source><volume>14</volume><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(01)00147-9</pub-id><pub-id pub-id-type="pmid">11420042</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname> <given-names>A</given-names></name><name><surname>Moniaux</surname> <given-names>N</given-names></name><name><surname>Ulrich</surname> <given-names>AB</given-names></name><name><surname>Schmied</surname> <given-names>BM</given-names></name><name><surname>Standop</surname> <given-names>J</given-names></name><name><surname>Pour</surname> <given-names>PM</given-names></name><name><surname>Gendler</surname> <given-names>SJ</given-names></name><name><surname>Hollingsworth</surname> <given-names>MA</given-names></name><name><surname>Aubert</surname> <given-names>JP</given-names></name><name><surname>Batra</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>MUC4 mucin expression in human pancreatic tumours is affected by organ environment: the possible role of TGFbeta2</article-title><source>British Journal of Cancer</source><volume>90</volume><fpage>657</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601604</pub-id><pub-id pub-id-type="pmid">14760381</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciampricotti</surname> <given-names>M</given-names></name><name><surname>Hau</surname> <given-names>CS</given-names></name><name><surname>Doornebal</surname> <given-names>CW</given-names></name><name><surname>Jonkers</surname> <given-names>J</given-names></name><name><surname>de Visser</surname> <given-names>KE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system</article-title><source>Nature Medicine</source><volume>18</volume><fpage>344</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/nm.2652</pub-id><pub-id pub-id-type="pmid">22395693</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffelt</surname> <given-names>SB</given-names></name><name><surname>de Visser</surname> <given-names>KE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Immune-mediated mechanisms influencing the efficacy of anticancer therapies</article-title><source>Trends in Immunology</source><volume>36</volume><fpage>198</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.it.2015.02.006</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colegio</surname> <given-names>OR</given-names></name><name><surname>Chu</surname> <given-names>NQ</given-names></name><name><surname>Szabo</surname> <given-names>AL</given-names></name><name><surname>Chu</surname> <given-names>T</given-names></name><name><surname>Rhebergen</surname> <given-names>AM</given-names></name><name><surname>Jairam</surname> <given-names>V</given-names></name><name><surname>Cyrus</surname> <given-names>N</given-names></name><name><surname>Brokowski</surname> <given-names>CE</given-names></name><name><surname>Eisenbarth</surname> <given-names>SC</given-names></name><name><surname>Phillips</surname> <given-names>GM</given-names></name><name><surname>Cline</surname> <given-names>GW</given-names></name><name><surname>Phillips</surname> <given-names>AJ</given-names></name><name><surname>Medzhitov</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Functional polarization of tumour-associated macrophages by tumour-derived lactic acid</article-title><source>Nature</source><volume>513</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nature13490</pub-id><pub-id pub-id-type="pmid">25043024</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conlon</surname> <given-names>J</given-names></name><name><surname>Burdette</surname> <given-names>DL</given-names></name><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>Bhat</surname> <given-names>N</given-names></name><name><surname>Thompson</surname> <given-names>M</given-names></name><name><surname>Jiang</surname> <given-names>Z</given-names></name><name><surname>Rathinam</surname> <given-names>VA</given-names></name><name><surname>Monks</surname> <given-names>B</given-names></name><name><surname>Jin</surname> <given-names>T</given-names></name><name><surname>Xiao</surname> <given-names>TS</given-names></name><name><surname>Vogel</surname> <given-names>SN</given-names></name><name><surname>Vance</surname> <given-names>RE</given-names></name><name><surname>Fitzgerald</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid</article-title><source>The Journal of Immunology</source><volume>190</volume><fpage>5216</fpage><lpage>5225</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300097</pub-id><pub-id pub-id-type="pmid">23585680</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corcoran</surname> <given-names>RB</given-names></name><name><surname>Ebi</surname> <given-names>H</given-names></name><name><surname>Turke</surname> <given-names>AB</given-names></name><name><surname>Coffee</surname> <given-names>EM</given-names></name><name><surname>Nishino</surname> <given-names>M</given-names></name><name><surname>Cogdill</surname> <given-names>AP</given-names></name><name><surname>Brown</surname> <given-names>RD</given-names></name><name><surname>Della Pelle</surname> <given-names>P</given-names></name><name><surname>Dias-Santagata</surname> <given-names>D</given-names></name><name><surname>Hung</surname> <given-names>KE</given-names></name><name><surname>Flaherty</surname> <given-names>KT</given-names></name><name><surname>Piris</surname> <given-names>A</given-names></name><name><surname>Wargo</surname> <given-names>JA</given-names></name><name><surname>Settleman</surname> <given-names>J</given-names></name><name><surname>Mino-Kenudson</surname> <given-names>M</given-names></name><name><surname>Engelman</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of <italic>BRAF</italic> mutant colorectal cancers to RAF inhibition with vemurafenib</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-11-0341</pub-id><pub-id pub-id-type="pmid">22448344</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname> <given-names>W</given-names></name><name><surname>Kemp</surname> <given-names>CJ</given-names></name><name><surname>Duffie</surname> <given-names>E</given-names></name><name><surname>Balmain</surname> <given-names>A</given-names></name><name><surname>Akhurst</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion</article-title><source>Cancer Research</source><volume>54</volume><fpage>5831</fpage><lpage>5836</lpage><pub-id pub-id-type="pmid">7954410</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname> <given-names>CP</given-names></name><name><surname>Merlino</surname> <given-names>G</given-names></name><name><surname>Van Dyke</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Preclinical mouse Cancer models: a maze of opportunities and challenges</article-title><source>Cell</source><volume>163</volume><fpage>39</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.068</pub-id><pub-id pub-id-type="pmid">26406370</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Visser</surname> <given-names>KE</given-names></name><name><surname>Korets</surname> <given-names>LV</given-names></name><name><surname>Coussens</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent</article-title><source>Cancer Cell</source><volume>7</volume><fpage>411</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2005.04.014</pub-id><pub-id pub-id-type="pmid">15894262</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaud</surname> <given-names>C</given-names></name><name><surname>Westwood</surname> <given-names>JA</given-names></name><name><surname>John</surname> <given-names>LB</given-names></name><name><surname>Flynn</surname> <given-names>JK</given-names></name><name><surname>Paquet-Fifield</surname> <given-names>S</given-names></name><name><surname>Duong</surname> <given-names>CP</given-names></name><name><surname>Yong</surname> <given-names>CS</given-names></name><name><surname>Pegram</surname> <given-names>HJ</given-names></name><name><surname>Stacker</surname> <given-names>SA</given-names></name><name><surname>Achen</surname> <given-names>MG</given-names></name><name><surname>Stewart</surname> <given-names>TJ</given-names></name><name><surname>Snyder</surname> <given-names>LA</given-names></name><name><surname>Teng</surname> <given-names>MW</given-names></name><name><surname>Smyth</surname> <given-names>MJ</given-names></name><name><surname>Darcy</surname> <given-names>PK</given-names></name><name><surname>Kershaw</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy</article-title><source>Molecular Therapy</source><volume>22</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1038/mt.2013.219</pub-id><pub-id pub-id-type="pmid">24048441</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deweerdt</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Comparative biology: naked ambition</article-title><source>Nature</source><volume>509</volume><fpage>S60</fpage><lpage>S61</lpage><pub-id pub-id-type="doi">10.1038/509S60a</pub-id><pub-id pub-id-type="pmid">24870823</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Carlo</surname> <given-names>E</given-names></name><name><surname>Forni</surname> <given-names>G</given-names></name><name><surname>Lollini</surname> <given-names>P</given-names></name><name><surname>Colombo</surname> <given-names>MP</given-names></name><name><surname>Modesti</surname> <given-names>A</given-names></name><name><surname>Musiani</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The intriguing role of polymorphonuclear neutrophils in antitumor reactions</article-title><source>Blood</source><volume>97</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1182/blood.V97.2.339</pub-id><pub-id pub-id-type="pmid">11154206</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Mitri</surname> <given-names>D</given-names></name><name><surname>Toso</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>JJ</given-names></name><name><surname>Sarti</surname> <given-names>M</given-names></name><name><surname>Pinton</surname> <given-names>S</given-names></name><name><surname>Jost</surname> <given-names>TR</given-names></name><name><surname>D’Antuono</surname> <given-names>R</given-names></name><name><surname>Montani</surname> <given-names>E</given-names></name><name><surname>Garcia-Escudero</surname> <given-names>R</given-names></name><name><surname>Guccini</surname> <given-names>I</given-names></name><name><surname>Da Silva-Alvarez</surname> <given-names>S</given-names></name><name><surname>Collado</surname> <given-names>M</given-names></name><name><surname>Eisenberger</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Catapano</surname> <given-names>C</given-names></name><name><surname>Grassi</surname> <given-names>F</given-names></name><name><surname>Alimonti</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer</article-title><source>Nature</source><volume>515</volume><fpage>134</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1038/nature13638</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drees</surname> <given-names>JJ</given-names></name><name><surname>Mertensotto</surname> <given-names>MJ</given-names></name><name><surname>Augustin</surname> <given-names>LB</given-names></name><name><surname>Schottel</surname> <given-names>JL</given-names></name><name><surname>Saltzman</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Vasculature disruption enhances bacterial targeting of autochthonous tumors</article-title><source>Journal of Cancer</source><volume>6</volume><fpage>843</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.7150/jca.12491</pub-id><pub-id pub-id-type="pmid">26284135</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuPage</surname> <given-names>M</given-names></name><name><surname>Mazumdar</surname> <given-names>C</given-names></name><name><surname>Schmidt</surname> <given-names>LM</given-names></name><name><surname>Cheung</surname> <given-names>AF</given-names></name><name><surname>Jacks</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Expression of tumour-specific antigens underlies Cancer immunoediting</article-title><source>Nature</source><volume>482</volume><fpage>405</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1038/nature10803</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efremova</surname> <given-names>M</given-names></name><name><surname>Rieder</surname> <given-names>D</given-names></name><name><surname>Klepsch</surname> <given-names>V</given-names></name><name><surname>Charoentong</surname> <given-names>P</given-names></name><name><surname>Finotello</surname> <given-names>F</given-names></name><name><surname>Hackl</surname> <given-names>H</given-names></name><name><surname>Hermann-Kleiter</surname> <given-names>N</given-names></name><name><surname>Löwer</surname> <given-names>M</given-names></name><name><surname>Baier</surname> <given-names>G</given-names></name><name><surname>Krogsdam</surname> <given-names>A</given-names></name><name><surname>Trajanoski</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02424-0</pub-id><pub-id pub-id-type="pmid">29296022</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ercolini</surname> <given-names>AM</given-names></name><name><surname>Machiels</surname> <given-names>J-PH</given-names></name><name><surname>Chen</surname> <given-names>YC</given-names></name><name><surname>Slansky</surname> <given-names>JE</given-names></name><name><surname>Giedlen</surname> <given-names>M</given-names></name><name><surname>Reilly</surname> <given-names>RT</given-names></name><name><surname>Jaffee</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-Transgenic mice</article-title><source>The Journal of Immunology</source><volume>170</volume><fpage>4273</fpage><lpage>4280</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.8.4273</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esquerré</surname> <given-names>M</given-names></name><name><surname>Tauzin</surname> <given-names>B</given-names></name><name><surname>Guiraud</surname> <given-names>M</given-names></name><name><surname>Müller</surname> <given-names>S</given-names></name><name><surname>Saoudi</surname> <given-names>A</given-names></name><name><surname>Valitutti</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Human regulatory T cells inhibit polarization of T helper cells toward antigen-presenting cells via a TGF-beta-dependent mechanism</article-title><source>PNAS</source><volume>105</volume><fpage>2550</fpage><lpage>2555</lpage><pub-id pub-id-type="doi">10.1073/pnas.0708350105</pub-id><pub-id pub-id-type="pmid">18268354</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadok</surname> <given-names>VA</given-names></name><name><surname>Bratton</surname> <given-names>DL</given-names></name><name><surname>Konowal</surname> <given-names>A</given-names></name><name><surname>Freed</surname> <given-names>PW</given-names></name><name><surname>Westcott</surname> <given-names>JY</given-names></name><name><surname>Henson</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF</article-title><source>Journal of Clinical Investigation</source><volume>101</volume><fpage>890</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1172/JCI1112</pub-id><pub-id pub-id-type="pmid">9466984</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahlén</surname> <given-names>L</given-names></name><name><surname>Read</surname> <given-names>S</given-names></name><name><surname>Gorelik</surname> <given-names>L</given-names></name><name><surname>Hurst</surname> <given-names>SD</given-names></name><name><surname>Coffman</surname> <given-names>RL</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Powrie</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells</article-title><source>The Journal of Experimental Medicine</source><volume>201</volume><fpage>737</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1084/jem.20040685</pub-id><pub-id pub-id-type="pmid">15753207</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falk</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Differences in vascular pattern between the spontaneous and the transplanted C3H mouse mammary carcinoma</article-title><source>European Journal of Cancer and Clinical Oncology</source><volume>18</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/0277-5379(82)90059-1</pub-id><pub-id pub-id-type="pmid">7201391</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feig</surname> <given-names>C</given-names></name><name><surname>Jones</surname> <given-names>JO</given-names></name><name><surname>Kraman</surname> <given-names>M</given-names></name><name><surname>Wells</surname> <given-names>RJ</given-names></name><name><surname>Deonarine</surname> <given-names>A</given-names></name><name><surname>Chan</surname> <given-names>DS</given-names></name><name><surname>Connell</surname> <given-names>CM</given-names></name><name><surname>Roberts</surname> <given-names>EW</given-names></name><name><surname>Zhao</surname> <given-names>Q</given-names></name><name><surname>Caballero</surname> <given-names>OL</given-names></name><name><surname>Teichmann</surname> <given-names>SA</given-names></name><name><surname>Janowitz</surname> <given-names>T</given-names></name><name><surname>Jodrell</surname> <given-names>DI</given-names></name><name><surname>Tuveson</surname> <given-names>DA</given-names></name><name><surname>Fearon</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic Cancer</article-title><source>PNAS</source><volume>110</volume><fpage>20212</fpage><lpage>20217</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320318110</pub-id><pub-id pub-id-type="pmid">24277834</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenton</surname> <given-names>BM</given-names></name><name><surname>Lord</surname> <given-names>EM</given-names></name><name><surname>Paoni</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Intravascular HbO2 saturations, perfusion and hypoxia in spontaneous and transplanted tumor models</article-title><source>International Journal of Cancer</source><volume>93</volume><fpage>693</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1002/ijc.1401</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenton</surname> <given-names>BM</given-names></name><name><surname>Paoni</surname> <given-names>SF</given-names></name><name><surname>Ding</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors</article-title><source>Radiotherapy and Oncology</source><volume>72</volume><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2004.05.005</pub-id><pub-id pub-id-type="pmid">15297140</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenton</surname> <given-names>BM</given-names></name><name><surname>Paoni</surname> <given-names>SF</given-names></name><name><surname>Grimwood</surname> <given-names>B</given-names></name><name><surname>Ding</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Varied response of spontaneous tumors to antiangiogenic agents</article-title><source>Advances in Experimental Medicine and Biology</source><volume>566</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/0-387-26206-7_9</pub-id><pub-id pub-id-type="pmid">16594135</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname> <given-names>IJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The pathogenesis of Cancer metastasis: the 'seed and soil' hypothesis revisited</article-title><source>Nature Reviews Cancer</source><volume>3</volume><fpage>453</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/nrc1098</pub-id><pub-id pub-id-type="pmid">12778135</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1971">1971</year><article-title>Tumor angiogenesis: therapeutic implications</article-title><source>The New England Journal of Medicine</source><volume>285</volume><fpage>1182</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1056/NEJM197111182852108</pub-id><pub-id pub-id-type="pmid">4938153</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Role of angiogenesis in tumor growth and metastasis</article-title><source>Seminars in Oncology</source><volume>29</volume><fpage>15</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1053/sonc.2002.37263</pub-id><pub-id pub-id-type="pmid">12516034</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname> <given-names>J</given-names></name><name><surname>Hanahan</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Switch to the angiogenic phenotype during tumorigenesis</article-title><source>Princess Takamatsu Symposia</source><volume>22</volume><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">1726933</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>BA</given-names></name><name><surname>Gingrich</surname> <given-names>JR</given-names></name><name><surname>Kwon</surname> <given-names>ED</given-names></name><name><surname>Madias</surname> <given-names>C</given-names></name><name><surname>Greenberg</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model</article-title><source>Cancer Research</source><volume>57</volume><fpage>3325</fpage><lpage>3330</lpage><pub-id pub-id-type="pmid">9269988</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname> <given-names>RA</given-names></name><name><surname>Liao</surname> <given-names>W</given-names></name><name><surname>Sarkar</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>MV</given-names></name><name><surname>Bivona</surname> <given-names>MR</given-names></name><name><surname>Liu</surname> <given-names>K</given-names></name><name><surname>Pamer</surname> <given-names>EG</given-names></name><name><surname>Li</surname> <given-names>MO</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The cellular and molecular origin of tumor-associated macrophages</article-title><source>Science</source><volume>344</volume><fpage>921</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1126/science.1252510</pub-id><pub-id pub-id-type="pmid">24812208</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frese</surname> <given-names>KK</given-names></name><name><surname>Tuveson</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Maximizing mouse cancer models</article-title><source>Nature Reviews Cancer</source><volume>7</volume><fpage>654</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1038/nrc2192</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname> <given-names>AS</given-names></name><name><surname>Lee</surname> <given-names>C</given-names></name><name><surname>Yu</surname> <given-names>M</given-names></name><name><surname>Tannock</surname> <given-names>IF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts</article-title><source>BMC Cancer</source><volume>15</volume><elocation-id>112</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-015-1091-6</pub-id><pub-id pub-id-type="pmid">25884767</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galluzzi</surname> <given-names>L</given-names></name><name><surname>Buqué</surname> <given-names>A</given-names></name><name><surname>Kepp</surname> <given-names>O</given-names></name><name><surname>Zitvogel</surname> <given-names>L</given-names></name><name><surname>Kroemer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Immunogenic cell death in cancer and infectious disease</article-title><source>Nature Reviews Immunology</source><volume>17</volume><fpage>97</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.107</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gee</surname> <given-names>MS</given-names></name><name><surname>Procopio</surname> <given-names>WN</given-names></name><name><surname>Makonnen</surname> <given-names>S</given-names></name><name><surname>Feldman</surname> <given-names>MD</given-names></name><name><surname>Yeilding</surname> <given-names>NM</given-names></name><name><surname>Lee</surname> <given-names>WM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy</article-title><source>The American Journal of Pathology</source><volume>162</volume><fpage>183</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63809-6</pub-id><pub-id pub-id-type="pmid">12507901</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germano</surname> <given-names>G</given-names></name><name><surname>Lamba</surname> <given-names>S</given-names></name><name><surname>Rospo</surname> <given-names>G</given-names></name><name><surname>Barault</surname> <given-names>L</given-names></name><name><surname>Magrì</surname> <given-names>A</given-names></name><name><surname>Maione</surname> <given-names>F</given-names></name><name><surname>Russo</surname> <given-names>M</given-names></name><name><surname>Crisafulli</surname> <given-names>G</given-names></name><name><surname>Bartolini</surname> <given-names>A</given-names></name><name><surname>Lerda</surname> <given-names>G</given-names></name><name><surname>Siravegna</surname> <given-names>G</given-names></name><name><surname>Mussolin</surname> <given-names>B</given-names></name><name><surname>Frapolli</surname> <given-names>R</given-names></name><name><surname>Montone</surname> <given-names>M</given-names></name><name><surname>Morano</surname> <given-names>F</given-names></name><name><surname>de Braud</surname> <given-names>F</given-names></name><name><surname>Amirouchene-Angelozzi</surname> <given-names>N</given-names></name><name><surname>Marsoni</surname> <given-names>S</given-names></name><name><surname>D'Incalci</surname> <given-names>M</given-names></name><name><surname>Orlandi</surname> <given-names>A</given-names></name><name><surname>Giraudo</surname> <given-names>E</given-names></name><name><surname>Sartore-Bianchi</surname> <given-names>A</given-names></name><name><surname>Siena</surname> <given-names>S</given-names></name><name><surname>Pietrantonio</surname> <given-names>F</given-names></name><name><surname>Di Nicolantonio</surname> <given-names>F</given-names></name><name><surname>Bardelli</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth</article-title><source>Nature</source><volume>552</volume><fpage>116</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/nature24673</pub-id><pub-id pub-id-type="pmid">29186113</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimbrone</surname> <given-names>MA</given-names></name><name><surname>Aster</surname> <given-names>RH</given-names></name><name><surname>Cotran</surname> <given-names>RS</given-names></name><name><surname>Corkery</surname> <given-names>J</given-names></name><name><surname>Jandl</surname> <given-names>JH</given-names></name><name><surname>Folkman</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium</article-title><source>Nature</source><volume>222</volume><fpage>33</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/222033a0</pub-id><pub-id pub-id-type="pmid">5775827</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The role for transforming growth factor-beta (TGF-beta) in human Cancer</article-title><source>Critical Reviews in Oncogenesis</source><volume>10</volume><fpage>303</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">10654929</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="1941">1941</year><article-title>Heterologous transplantation of mammalian tumors : I. the transfer of rabbit tumors to alien species</article-title><source>The Journal of Experimental Medicine</source><volume>73</volume><fpage>461</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1084/jem.73.4.461</pub-id><pub-id pub-id-type="pmid">19871090</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gros</surname> <given-names>A</given-names></name><name><surname>Parkhurst</surname> <given-names>MR</given-names></name><name><surname>Tran</surname> <given-names>E</given-names></name><name><surname>Pasetto</surname> <given-names>A</given-names></name><name><surname>Robbins</surname> <given-names>PF</given-names></name><name><surname>Ilyas</surname> <given-names>S</given-names></name><name><surname>Prickett</surname> <given-names>TD</given-names></name><name><surname>Gartner</surname> <given-names>JJ</given-names></name><name><surname>Crystal</surname> <given-names>JS</given-names></name><name><surname>Roberts</surname> <given-names>IM</given-names></name><name><surname>Trebska-McGowan</surname> <given-names>K</given-names></name><name><surname>Wunderlich</surname> <given-names>JR</given-names></name><name><surname>Yang</surname> <given-names>JC</given-names></name><name><surname>Rosenberg</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients</article-title><source>Nature Medicine</source><volume>22</volume><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/nm.4051</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerin</surname> <given-names>MV</given-names></name><name><surname>Regnier</surname> <given-names>F</given-names></name><name><surname>Feuillet</surname> <given-names>V</given-names></name><name><surname>Vimeux</surname> <given-names>L</given-names></name><name><surname>Weiss</surname> <given-names>JM</given-names></name><name><surname>Bismuth</surname> <given-names>G</given-names></name><name><surname>Altan-Bonnet</surname> <given-names>G</given-names></name><name><surname>Guilbert</surname> <given-names>T</given-names></name><name><surname>Thoreau</surname> <given-names>M</given-names></name><name><surname>Finisguerra</surname> <given-names>V</given-names></name><name><surname>Donnadieu</surname> <given-names>E</given-names></name><name><surname>Trautmann</surname> <given-names>A</given-names></name><name><surname>Bercovici</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tgfβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4131</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11998-w</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname> <given-names>D</given-names></name><name><surname>Folkman</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis</article-title><source>Cell</source><volume>86</volume><fpage>353</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80108-7</pub-id><pub-id pub-id-type="pmid">8756718</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmaier</surname> <given-names>RJ</given-names></name><name><surname>Charo</surname> <given-names>J</given-names></name><name><surname>Fabrizio</surname> <given-names>D</given-names></name><name><surname>Goldberg</surname> <given-names>ME</given-names></name><name><surname>Albacker</surname> <given-names>LA</given-names></name><name><surname>Pao</surname> <given-names>W</given-names></name><name><surname>Chmielecki</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted Cancer immunotherapy strategies</article-title><source>Genome Medicine</source><volume>9</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-017-0408-2</pub-id><pub-id pub-id-type="pmid">28231819</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Havas</surname> <given-names>HF</given-names></name><name><surname>Donnelly</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="1961">1961</year><article-title>Mixed bacterial toxins in the treatment of tumors. IV. response of methylcholanthrene-induced, spontaneous, and transplanted tumors in mice</article-title><source>Cancer Research</source><volume>21</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">13712361</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirai</surname> <given-names>T</given-names></name><name><surname>Zenke</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Bartholin</surname> <given-names>L</given-names></name><name><surname>Beura</surname> <given-names>LK</given-names></name><name><surname>Masopust</surname> <given-names>D</given-names></name><name><surname>Kaplan</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Keratinocyte-Mediated activation of the cytokine TGF-β maintains skin recirculating memory CD8<sup>+</sup> T Cells</article-title><source>Immunity</source><volume>50</volume><fpage>1249</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.002</pub-id><pub-id pub-id-type="pmid">30952606</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="1962">1962</year><article-title>Some aspects of the problem of immunity against transplanted and spontaneous tumors</article-title><source>Bacteriological Reviews</source><volume>26</volume><fpage>336</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1128/MMBR.26.3.336-353.1962</pub-id><pub-id pub-id-type="pmid">13961186</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The molecular and mathematical basis of Waddington's epigenetic landscape: a framework for post-Darwinian biology?</article-title><source>BioEssays</source><volume>34</volume><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1002/bies.201100031</pub-id><pub-id pub-id-type="pmid">22102361</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugo</surname> <given-names>W</given-names></name><name><surname>Zaretsky</surname> <given-names>JM</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Moreno</surname> <given-names>BH</given-names></name><name><surname>Hu-Lieskovan</surname> <given-names>S</given-names></name><name><surname>Berent-Maoz</surname> <given-names>B</given-names></name><name><surname>Pang</surname> <given-names>J</given-names></name><name><surname>Chmielowski</surname> <given-names>B</given-names></name><name><surname>Cherry</surname> <given-names>G</given-names></name><name><surname>Seja</surname> <given-names>E</given-names></name><name><surname>Lomeli</surname> <given-names>S</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Kelley</surname> <given-names>MC</given-names></name><name><surname>Sosman</surname> <given-names>JA</given-names></name><name><surname>Johnson</surname> <given-names>DB</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>Lo</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma</article-title><source>Cell</source><volume>165</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.02.065</pub-id><pub-id pub-id-type="pmid">26997480</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huijbers</surname> <given-names>IJ</given-names></name><name><surname>Krimpenfort</surname> <given-names>P</given-names></name><name><surname>Chomez</surname> <given-names>P</given-names></name><name><surname>van der Valk</surname> <given-names>MA</given-names></name><name><surname>Song</surname> <given-names>JY</given-names></name><name><surname>Inderberg-Suso</surname> <given-names>EM</given-names></name><name><surname>Schmitt-Verhulst</surname> <given-names>AM</given-names></name><name><surname>Berns</surname> <given-names>A</given-names></name><name><surname>Van den Eynde</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>An inducible mouse model of melanoma expressing a defined tumor antigen</article-title><source>Cancer Research</source><volume>66</volume><fpage>3278</fpage><lpage>3286</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3216</pub-id><pub-id pub-id-type="pmid">16540681</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huss</surname> <given-names>WJ</given-names></name><name><surname>Barrios</surname> <given-names>RJ</given-names></name><name><surname>Greenberg</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis</article-title><source>Molecular Cancer Therapeutics</source><volume>2</volume><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">12883033</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joncker</surname> <given-names>NT</given-names></name><name><surname>Bettini</surname> <given-names>S</given-names></name><name><surname>Boulet</surname> <given-names>D</given-names></name><name><surname>Guiraud</surname> <given-names>M</given-names></name><name><surname>Guerder</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The site of tumor development determines immunogenicity via temporal mobilization of antigen-laden dendritic cells in draining lymph nodes</article-title><source>European Journal of Immunology</source><volume>46</volume><fpage>609</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1002/eji.201545797</pub-id><pub-id pub-id-type="pmid">26626316</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keren</surname> <given-names>L</given-names></name><name><surname>Bosse</surname> <given-names>M</given-names></name><name><surname>Marquez</surname> <given-names>D</given-names></name><name><surname>Angoshtari</surname> <given-names>R</given-names></name><name><surname>Jain</surname> <given-names>S</given-names></name><name><surname>Varma</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>SR</given-names></name><name><surname>Kurian</surname> <given-names>A</given-names></name><name><surname>Van Valen</surname> <given-names>D</given-names></name><name><surname>West</surname> <given-names>R</given-names></name><name><surname>Bendall</surname> <given-names>SC</given-names></name><name><surname>Angelo</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A structured Tumor-Immune microenvironment in triple negative breast Cancer revealed by multiplexed ion beam imaging</article-title><source>Cell</source><volume>174</volume><fpage>1373</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.08.039</pub-id><pub-id pub-id-type="pmid">30193111</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kersten</surname> <given-names>K</given-names></name><name><surname>de Visser</surname> <given-names>KE</given-names></name><name><surname>van Miltenburg</surname> <given-names>MH</given-names></name><name><surname>Jonkers</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetically engineered mouse models in oncology research and Cancer medicine</article-title><source>EMBO Molecular Medicine</source><volume>9</volume><fpage>137</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.15252/emmm.201606857</pub-id><pub-id pub-id-type="pmid">28028012</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohl</surname> <given-names>NE</given-names></name><name><surname>Omer</surname> <given-names>CA</given-names></name><name><surname>Conner</surname> <given-names>MW</given-names></name><name><surname>Anthony</surname> <given-names>NJ</given-names></name><name><surname>Davide</surname> <given-names>JP</given-names></name><name><surname>deSolms</surname> <given-names>SJ</given-names></name><name><surname>Giuliani</surname> <given-names>EA</given-names></name><name><surname>Gomez</surname> <given-names>RP</given-names></name><name><surname>Graham</surname> <given-names>SL</given-names></name><name><surname>Hamilton</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice</article-title><source>Nature Medicine</source><volume>1</volume><fpage>792</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/nm0895-792</pub-id><pub-id pub-id-type="pmid">7585182</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraman</surname> <given-names>M</given-names></name><name><surname>Bambrough</surname> <given-names>PJ</given-names></name><name><surname>Arnold</surname> <given-names>JN</given-names></name><name><surname>Roberts</surname> <given-names>EW</given-names></name><name><surname>Magiera</surname> <given-names>L</given-names></name><name><surname>Jones</surname> <given-names>JO</given-names></name><name><surname>Gopinathan</surname> <given-names>A</given-names></name><name><surname>Tuveson</surname> <given-names>DA</given-names></name><name><surname>Fearon</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha</article-title><source>Science</source><volume>330</volume><fpage>827</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1126/science.1195300</pub-id><pub-id pub-id-type="pmid">21051638</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuperwasser</surname> <given-names>C</given-names></name><name><surname>Chavarria</surname> <given-names>T</given-names></name><name><surname>Wu</surname> <given-names>M</given-names></name><name><surname>Magrane</surname> <given-names>G</given-names></name><name><surname>Gray</surname> <given-names>JW</given-names></name><name><surname>Carey</surname> <given-names>L</given-names></name><name><surname>Richardson</surname> <given-names>A</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Reconstruction of functionally normal and malignant human breast tissues in mice</article-title><source>PNAS</source><volume>101</volume><fpage>4966</fpage><lpage>4971</lpage><pub-id pub-id-type="doi">10.1073/pnas.0401064101</pub-id><pub-id pub-id-type="pmid">15051869</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanfredini</surname> <given-names>S</given-names></name><name><surname>Thapa</surname> <given-names>A</given-names></name><name><surname>O'Neill</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RAS in pancreatic cancer</article-title><source>Biochemical Society Transactions</source><volume>47</volume><fpage>961</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1042/BST20170521</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lara</surname> <given-names>PN</given-names></name><name><surname>Douillard</surname> <given-names>JY</given-names></name><name><surname>Nakagawa</surname> <given-names>K</given-names></name><name><surname>von Pawel</surname> <given-names>J</given-names></name><name><surname>McKeage</surname> <given-names>MJ</given-names></name><name><surname>Albert</surname> <given-names>I</given-names></name><name><surname>Losonczy</surname> <given-names>G</given-names></name><name><surname>Reck</surname> <given-names>M</given-names></name><name><surname>Heo</surname> <given-names>DS</given-names></name><name><surname>Fan</surname> <given-names>X</given-names></name><name><surname>Fandi</surname> <given-names>A</given-names></name><name><surname>Scagliotti</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung Cancer</article-title><source>Journal of Clinical Oncology</source><volume>29</volume><fpage>2965</fpage><lpage>2971</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.35.0660</pub-id><pub-id pub-id-type="pmid">21709202</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Stojanov</surname> <given-names>P</given-names></name><name><surname>Polak</surname> <given-names>P</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Sivachenko</surname> <given-names>A</given-names></name><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Stewart</surname> <given-names>C</given-names></name><name><surname>Mermel</surname> <given-names>CH</given-names></name><name><surname>Roberts</surname> <given-names>SA</given-names></name><name><surname>Kiezun</surname> <given-names>A</given-names></name><name><surname>Hammerman</surname> <given-names>PS</given-names></name><name><surname>McKenna</surname> <given-names>A</given-names></name><name><surname>Drier</surname> <given-names>Y</given-names></name><name><surname>Zou</surname> <given-names>L</given-names></name><name><surname>Ramos</surname> <given-names>AH</given-names></name><name><surname>Pugh</surname> <given-names>TJ</given-names></name><name><surname>Stransky</surname> <given-names>N</given-names></name><name><surname>Helman</surname> <given-names>E</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Ambrogio</surname> <given-names>L</given-names></name><name><surname>Nickerson</surname> <given-names>E</given-names></name><name><surname>Shefler</surname> <given-names>E</given-names></name><name><surname>Cortés</surname> <given-names>ML</given-names></name><name><surname>Auclair</surname> <given-names>D</given-names></name><name><surname>Saksena</surname> <given-names>G</given-names></name><name><surname>Voet</surname> <given-names>D</given-names></name><name><surname>Noble</surname> <given-names>M</given-names></name><name><surname>DiCara</surname> <given-names>D</given-names></name><name><surname>Lin</surname> <given-names>P</given-names></name><name><surname>Lichtenstein</surname> <given-names>L</given-names></name><name><surname>Heiman</surname> <given-names>DI</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Hernandez</surname> <given-names>B</given-names></name><name><surname>Hodis</surname> <given-names>E</given-names></name><name><surname>Baca</surname> <given-names>S</given-names></name><name><surname>Dulak</surname> <given-names>AM</given-names></name><name><surname>Lohr</surname> <given-names>J</given-names></name><name><surname>Landau</surname> <given-names>DA</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Melendez-Zajgla</surname> <given-names>J</given-names></name><name><surname>Hidalgo-Miranda</surname> <given-names>A</given-names></name><name><surname>Koren</surname> <given-names>A</given-names></name><name><surname>McCarroll</surname> <given-names>SA</given-names></name><name><surname>Mora</surname> <given-names>J</given-names></name><name><surname>Crompton</surname> <given-names>B</given-names></name><name><surname>Onofrio</surname> <given-names>R</given-names></name><name><surname>Parkin</surname> <given-names>M</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Roberts</surname> <given-names>CWM</given-names></name><name><surname>Biegel</surname> <given-names>JA</given-names></name><name><surname>Stegmaier</surname> <given-names>K</given-names></name><name><surname>Bass</surname> <given-names>AJ</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Gordenin</surname> <given-names>DA</given-names></name><name><surname>Sunyaev</surname> <given-names>S</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational heterogeneity in Cancer and the search for new cancer-associated genes</article-title><source>Nature</source><volume>499</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature12213</pub-id><pub-id pub-id-type="pmid">23770567</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JC</given-names></name><name><surname>Kim</surname> <given-names>DC</given-names></name><name><surname>Gee</surname> <given-names>MS</given-names></name><name><surname>Saunders</surname> <given-names>HM</given-names></name><name><surname>Sehgal</surname> <given-names>CM</given-names></name><name><surname>Feldman</surname> <given-names>MD</given-names></name><name><surname>Ross</surname> <given-names>SR</given-names></name><name><surname>Lee</surname> <given-names>WM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas</article-title><source>Cancer Research</source><volume>62</volume><fpage>747</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">11830529</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite de Oliveira</surname> <given-names>R</given-names></name><name><surname>Hamm</surname> <given-names>A</given-names></name><name><surname>Mazzone</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted Cancer therapies</article-title><source>Molecular Aspects of Medicine</source><volume>32</volume><fpage>71</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2011.04.001</pub-id><pub-id pub-id-type="pmid">21540050</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenferink</surname> <given-names>AE</given-names></name><name><surname>Simpson</surname> <given-names>JF</given-names></name><name><surname>Shawver</surname> <given-names>LK</given-names></name><name><surname>Coffey</surname> <given-names>RJ</given-names></name><name><surname>Forbes</surname> <given-names>JT</given-names></name><name><surname>Arteaga</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice</article-title><source>PNAS</source><volume>97</volume><fpage>9609</fpage><lpage>9614</lpage><pub-id pub-id-type="doi">10.1073/pnas.160564197</pub-id><pub-id pub-id-type="pmid">10931950</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Blake</surname> <given-names>SJ</given-names></name><name><surname>Smyth</surname> <given-names>MJ</given-names></name><name><surname>Teng</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved mouse models to assess tumour immunity and irAEs after combination Cancer immunotherapies</article-title><source>Clinical &amp; Translational Immunology</source><volume>3</volume><elocation-id>e22</elocation-id><pub-id pub-id-type="doi">10.1038/cti.2014.18</pub-id><pub-id pub-id-type="pmid">25505970</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Yin</surname> <given-names>T</given-names></name><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Cona</surname> <given-names>MM</given-names></name><name><surname>Huang</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Song</surname> <given-names>S</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Xia</surname> <given-names>Q</given-names></name><name><surname>Swinnen</surname> <given-names>JV</given-names></name><name><surname>Bormans</surname> <given-names>G</given-names></name><name><surname>Himmelreich</surname> <given-names>U</given-names></name><name><surname>Oyen</surname> <given-names>R</given-names></name><name><surname>Ni</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research</article-title><source>Quantitative Imaging in Medicine and Surgery</source><volume>5</volume><fpage>708</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.3978/j.issn.2223-4292.2015.06.01</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Mattarollo</surname> <given-names>SR</given-names></name><name><surname>Adjemian</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Aymeric</surname> <given-names>L</given-names></name><name><surname>Hannani</surname> <given-names>D</given-names></name><name><surname>Portela Catani</surname> <given-names>JP</given-names></name><name><surname>Duret</surname> <given-names>H</given-names></name><name><surname>Teng</surname> <given-names>MW</given-names></name><name><surname>Kepp</surname> <given-names>O</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Sistigu</surname> <given-names>A</given-names></name><name><surname>Schultze</surname> <given-names>JL</given-names></name><name><surname>Stoll</surname> <given-names>G</given-names></name><name><surname>Galluzzi</surname> <given-names>L</given-names></name><name><surname>Zitvogel</surname> <given-names>L</given-names></name><name><surname>Smyth</surname> <given-names>MJ</given-names></name><name><surname>Kroemer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy</article-title><source>Cancer Research</source><volume>74</volume><fpage>436</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1265</pub-id><pub-id pub-id-type="pmid">24302580</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname> <given-names>H</given-names></name><name><surname>Vesely</surname> <given-names>MD</given-names></name><name><surname>Koboldt</surname> <given-names>DC</given-names></name><name><surname>Rickert</surname> <given-names>CG</given-names></name><name><surname>Uppaluri</surname> <given-names>R</given-names></name><name><surname>Magrini</surname> <given-names>VJ</given-names></name><name><surname>Arthur</surname> <given-names>CD</given-names></name><name><surname>White</surname> <given-names>JM</given-names></name><name><surname>Chen</surname> <given-names>Y-S</given-names></name><name><surname>Shea</surname> <given-names>LK</given-names></name><name><surname>Hundal</surname> <given-names>J</given-names></name><name><surname>Wendl</surname> <given-names>MC</given-names></name><name><surname>Demeter</surname> <given-names>R</given-names></name><name><surname>Wylie</surname> <given-names>T</given-names></name><name><surname>Allison</surname> <given-names>JP</given-names></name><name><surname>Smyth</surname> <given-names>MJ</given-names></name><name><surname>Old</surname> <given-names>LJ</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name><name><surname>Schreiber</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cancer exome analysis reveals a T-cell-dependent mechanism of Cancer immunoediting</article-title><source>Nature</source><volume>482</volume><fpage>400</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/nature10755</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCredie</surname> <given-names>JA</given-names></name><name><surname>Inch</surname> <given-names>WR</given-names></name><name><surname>Sutherland</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="1971">1971</year><article-title>Differences in growth and morphology between the spontaneous C3H mammary carcinoma in the mouse and its syngeneic transplants</article-title><source>Cancer</source><volume>27</volume><fpage>635</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197103)27:3&lt;635::AID-CNCR2820270319&gt;3.0.CO;2-F</pub-id><pub-id pub-id-type="pmid">5549497</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname> <given-names>N</given-names></name><name><surname>Furness</surname> <given-names>AJ</given-names></name><name><surname>Rosenthal</surname> <given-names>R</given-names></name><name><surname>Ramskov</surname> <given-names>S</given-names></name><name><surname>Lyngaa</surname> <given-names>R</given-names></name><name><surname>Saini</surname> <given-names>SK</given-names></name><name><surname>Jamal-Hanjani</surname> <given-names>M</given-names></name><name><surname>Wilson</surname> <given-names>GA</given-names></name><name><surname>Birkbak</surname> <given-names>NJ</given-names></name><name><surname>Hiley</surname> <given-names>CT</given-names></name><name><surname>Watkins</surname> <given-names>TB</given-names></name><name><surname>Shafi</surname> <given-names>S</given-names></name><name><surname>Murugaesu</surname> <given-names>N</given-names></name><name><surname>Mitter</surname> <given-names>R</given-names></name><name><surname>Akarca</surname> <given-names>AU</given-names></name><name><surname>Linares</surname> <given-names>J</given-names></name><name><surname>Marafioti</surname> <given-names>T</given-names></name><name><surname>Henry</surname> <given-names>JY</given-names></name><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>Miao</surname> <given-names>D</given-names></name><name><surname>Schilling</surname> <given-names>B</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Makarov</surname> <given-names>V</given-names></name><name><surname>Rizvi</surname> <given-names>NA</given-names></name><name><surname>Snyder</surname> <given-names>A</given-names></name><name><surname>Hellmann</surname> <given-names>MD</given-names></name><name><surname>Merghoub</surname> <given-names>T</given-names></name><name><surname>Wolchok</surname> <given-names>JD</given-names></name><name><surname>Shukla</surname> <given-names>SA</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Peggs</surname> <given-names>KS</given-names></name><name><surname>Chan</surname> <given-names>TA</given-names></name><name><surname>Hadrup</surname> <given-names>SR</given-names></name><name><surname>Quezada</surname> <given-names>SA</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade</article-title><source>Science</source><volume>351</volume><fpage>1463</fpage><lpage>1469</lpage><pub-id pub-id-type="doi">10.1126/science.aaf1490</pub-id><pub-id pub-id-type="pmid">26940869</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moustakas</surname> <given-names>A</given-names></name><name><surname>Pardali</surname> <given-names>K</given-names></name><name><surname>Gaal</surname> <given-names>A</given-names></name><name><surname>Heldin</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation</article-title><source>Immunology Letters</source><volume>82</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/S0165-2478(02)00023-8</pub-id><pub-id pub-id-type="pmid">12008039</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname> <given-names>MM</given-names></name><name><surname>Fusenig</surname> <given-names>NE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Friends or foes - bipolar effects of the tumour stroma in Cancer</article-title><source>Nature Reviews Cancer</source><volume>4</volume><fpage>839</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1038/nrc1477</pub-id><pub-id pub-id-type="pmid">15516957</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazareth</surname> <given-names>MR</given-names></name><name><surname>Broderick</surname> <given-names>L</given-names></name><name><surname>Simpson-Abelson</surname> <given-names>MR</given-names></name><name><surname>Kelleher</surname> <given-names>RJ</given-names></name><name><surname>Yokota</surname> <given-names>SJ</given-names></name><name><surname>Bankert</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells</article-title><source>The Journal of Immunology</source><volume>178</volume><fpage>5552</fpage><lpage>5562</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.9.5552</pub-id><pub-id pub-id-type="pmid">17442937</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguchi</surname> <given-names>T</given-names></name><name><surname>Ward</surname> <given-names>JP</given-names></name><name><surname>Gubin</surname> <given-names>MM</given-names></name><name><surname>Arthur</surname> <given-names>CD</given-names></name><name><surname>Lee</surname> <given-names>SH</given-names></name><name><surname>Hundal</surname> <given-names>J</given-names></name><name><surname>Selby</surname> <given-names>MJ</given-names></name><name><surname>Graziano</surname> <given-names>RF</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name><name><surname>Korman</surname> <given-names>AJ</given-names></name><name><surname>Schreiber</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape</article-title><source>Cancer Immunology Research</source><volume>5</volume><fpage>106</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0391</pub-id><pub-id pub-id-type="pmid">28073774</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Old</surname> <given-names>LJ</given-names></name><name><surname>Benacerraf</surname> <given-names>B</given-names></name><name><surname>Clarke</surname> <given-names>DA</given-names></name><name><surname>Carswell</surname> <given-names>EA</given-names></name><name><surname>Stockert</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1961">1961</year><article-title>The role of the reticuloendothelial system in the host reaction to neoplasia</article-title><source>Cancer Research</source><volume>21</volume><fpage>1281</fpage><lpage>1300</lpage><pub-id pub-id-type="pmid">14481701</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname> <given-names>B</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>ET</given-names></name><name><surname>Patnaik</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mouse models for Cancer immunotherapy research</article-title><source>Cancer Discovery</source><volume>8</volume><fpage>1358</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0044</pub-id><pub-id pub-id-type="pmid">30309862</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxenhandler</surname> <given-names>RW</given-names></name><name><surname>Berkelhammer</surname> <given-names>J</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Hook</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Growth and regression of cutaneous melanomas in sinclair miniature swine</article-title><source>The American Journal of Pathology</source><volume>109</volume><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">6758603</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pao</surname> <given-names>W</given-names></name><name><surname>Ooi</surname> <given-names>CH</given-names></name><name><surname>Birzele</surname> <given-names>F</given-names></name><name><surname>Ruefli-Brasse</surname> <given-names>A</given-names></name><name><surname>Cannarile</surname> <given-names>MA</given-names></name><name><surname>Reis</surname> <given-names>B</given-names></name><name><surname>Scharf</surname> <given-names>SH</given-names></name><name><surname>Schubert</surname> <given-names>DA</given-names></name><name><surname>Hatje</surname> <given-names>K</given-names></name><name><surname>Pelletier</surname> <given-names>N</given-names></name><name><surname>Spleiss</surname> <given-names>O</given-names></name><name><surname>Reed</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tissue-Specific immunoregulation: a call for better understanding of the &quot;Immunostat&quot; in the Context of Cancer</article-title><source>Cancer Discovery</source><volume>8</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1320</pub-id><pub-id pub-id-type="pmid">29545369</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penny</surname> <given-names>HL</given-names></name><name><surname>Sieow</surname> <given-names>JL</given-names></name><name><surname>Adriani</surname> <given-names>G</given-names></name><name><surname>Yeap</surname> <given-names>WH</given-names></name><name><surname>See Chi Ee</surname> <given-names>P</given-names></name><name><surname>San Luis</surname> <given-names>B</given-names></name><name><surname>Lee</surname> <given-names>B</given-names></name><name><surname>Lee</surname> <given-names>T</given-names></name><name><surname>Mak</surname> <given-names>SY</given-names></name><name><surname>Ho</surname> <given-names>YS</given-names></name><name><surname>Lam</surname> <given-names>KP</given-names></name><name><surname>Ong</surname> <given-names>CK</given-names></name><name><surname>Huang</surname> <given-names>RY</given-names></name><name><surname>Ginhoux</surname> <given-names>F</given-names></name><name><surname>Rotzschke</surname> <given-names>O</given-names></name><name><surname>Kamm</surname> <given-names>RD</given-names></name><name><surname>Wong</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma</article-title><source>OncoImmunology</source><volume>5</volume><elocation-id>e1191731</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2016.1191731</pub-id><pub-id pub-id-type="pmid">27622062</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez</surname> <given-names>J</given-names></name><name><surname>García</surname> <given-names>PM</given-names></name><name><surname>Bautista</surname> <given-names>MJ</given-names></name><name><surname>Millán</surname> <given-names>Y</given-names></name><name><surname>Ordás</surname> <given-names>J</given-names></name><name><surname>Martín de las Mulas</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Immunohistochemical characterization of tumor cells and inflammatory infiltrate associated with cutaneous melanocytic tumors of duroc and iberian swine</article-title><source>Veterinary Pathology</source><volume>39</volume><fpage>445</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1354/vp.39-4-445</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provenzano</surname> <given-names>PP</given-names></name><name><surname>Cuevas</surname> <given-names>C</given-names></name><name><surname>Chang</surname> <given-names>AE</given-names></name><name><surname>Goel</surname> <given-names>VK</given-names></name><name><surname>Von Hoff</surname> <given-names>DD</given-names></name><name><surname>Hingorani</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma</article-title><source>Cancer Cell</source><volume>21</volume><fpage>418</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.01.007</pub-id><pub-id pub-id-type="pmid">22439937</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname> <given-names>H</given-names></name><name><surname>Collazo</surname> <given-names>J</given-names></name><name><surname>Jones</surname> <given-names>E</given-names></name><name><surname>Gayheart</surname> <given-names>D</given-names></name><name><surname>Sakamoto</surname> <given-names>S</given-names></name><name><surname>Vogt</surname> <given-names>A</given-names></name><name><surname>Mitchell</surname> <given-names>B</given-names></name><name><surname>Kyprianou</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model</article-title><source>Cancer Research</source><volume>69</volume><fpage>7366</fpage><lpage>7374</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0758</pub-id><pub-id pub-id-type="pmid">19738062</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quiroga</surname> <given-names>D</given-names></name><name><surname>Lyerly</surname> <given-names>HK</given-names></name><name><surname>Morse</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Deficient mismatch repair and the role of immunotherapy in metastatic colorectal Cancer</article-title><source>Current Treatment Options in Oncology</source><volume>17</volume><elocation-id>41</elocation-id><pub-id pub-id-type="doi">10.1007/s11864-016-0414-4</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redmond</surname> <given-names>WL</given-names></name><name><surname>Linch</surname> <given-names>SN</given-names></name><name><surname>Kasiewicz</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity</article-title><source>Cancer Immunology Research</source><volume>2</volume><fpage>142</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0031-T</pub-id><pub-id pub-id-type="pmid">24778278</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname> <given-names>RT</given-names></name><name><surname>Gottlieb</surname> <given-names>MB</given-names></name><name><surname>Ercolini</surname> <given-names>AM</given-names></name><name><surname>Machiels</surname> <given-names>JP</given-names></name><name><surname>Kane</surname> <given-names>CE</given-names></name><name><surname>Okoye</surname> <given-names>FI</given-names></name><name><surname>Muller</surname> <given-names>WJ</given-names></name><name><surname>Dixon</surname> <given-names>KH</given-names></name><name><surname>Jaffee</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice</article-title><source>Cancer Research</source><volume>60</volume><fpage>3569</fpage><lpage>3576</lpage><pub-id pub-id-type="pmid">10910070</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname> <given-names>C</given-names></name><name><surname>Schachter</surname> <given-names>J</given-names></name><name><surname>Long</surname> <given-names>GV</given-names></name><name><surname>Arance</surname> <given-names>A</given-names></name><name><surname>Grob</surname> <given-names>JJ</given-names></name><name><surname>Mortier</surname> <given-names>L</given-names></name><name><surname>Daud</surname> <given-names>A</given-names></name><name><surname>Carlino</surname> <given-names>MS</given-names></name><name><surname>McNeil</surname> <given-names>C</given-names></name><name><surname>Lotem</surname> <given-names>M</given-names></name><name><surname>Larkin</surname> <given-names>J</given-names></name><name><surname>Lorigan</surname> <given-names>P</given-names></name><name><surname>Neyns</surname> <given-names>B</given-names></name><name><surname>Blank</surname> <given-names>CU</given-names></name><name><surname>Hamid</surname> <given-names>O</given-names></name><name><surname>Mateus</surname> <given-names>C</given-names></name><name><surname>Shapira-Frommer</surname> <given-names>R</given-names></name><name><surname>Kosh</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Ibrahim</surname> <given-names>N</given-names></name><name><surname>Ebbinghaus</surname> <given-names>S</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><collab>KEYNOTE-006 investigators</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Pembrolizumab versus ipilimumab in advanced melanoma</article-title><source>New England Journal of Medicine</source><volume>372</volume><fpage>2521</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1503093</pub-id><pub-id pub-id-type="pmid">25891173</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rous</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1914">1914</year><article-title>The influence of diet on transplanted and spontaneous mouse tumors</article-title><source>The Journal of Experimental Medicine</source><volume>20</volume><fpage>433</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1084/jem.20.5.433</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjabi</surname> <given-names>S</given-names></name><name><surname>Mosaheb</surname> <given-names>MM</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells</article-title><source>Immunity</source><volume>31</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.04.020</pub-id><pub-id pub-id-type="pmid">19604492</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlingensiepen</surname> <given-names>KH</given-names></name><name><surname>Fischer-Blass</surname> <given-names>B</given-names></name><name><surname>Schmaus</surname> <given-names>S</given-names></name><name><surname>Ludwig</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors</article-title><source>Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer</source><volume>177</volume><fpage>137</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1007/978-3-540-71279-4_16</pub-id><pub-id pub-id-type="pmid">18084956</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname> <given-names>CA</given-names></name><name><surname>McCurrach</surname> <given-names>ME</given-names></name><name><surname>de Stanchina</surname> <given-names>E</given-names></name><name><surname>Wallace-Brodeur</surname> <given-names>RR</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>2670</fpage><lpage>2677</lpage><pub-id pub-id-type="doi">10.1101/gad.13.20.2670</pub-id><pub-id pub-id-type="pmid">10541553</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname> <given-names>TN</given-names></name><name><surname>Schreiber</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neoantigens in cancer immunotherapy</article-title><source>Science</source><volume>348</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id><pub-id pub-id-type="pmid">25838375</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevko</surname> <given-names>A</given-names></name><name><surname>Michels</surname> <given-names>T</given-names></name><name><surname>Vrohlings</surname> <given-names>M</given-names></name><name><surname>Umansky</surname> <given-names>L</given-names></name><name><surname>Beckhove</surname> <given-names>P</given-names></name><name><surname>Kato</surname> <given-names>M</given-names></name><name><surname>Shurin</surname> <given-names>GV</given-names></name><name><surname>Shurin</surname> <given-names>MR</given-names></name><name><surname>Umansky</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model</article-title><source>The Journal of Immunology</source><volume>190</volume><fpage>2464</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202781</pub-id><pub-id pub-id-type="pmid">23359505</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>P</given-names></name><name><surname>Allison</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The future of immune checkpoint therapy</article-title><source>Science</source><volume>348</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1126/science.aaa8172</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharpless</surname> <given-names>NE</given-names></name><name><surname>Depinho</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The mighty mouse: genetically engineered mouse models in Cancer drug development</article-title><source>Nature Reviews Drug Discovery</source><volume>5</volume><fpage>741</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1038/nrd2110</pub-id><pub-id pub-id-type="pmid">16915232</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>Q</given-names></name><name><surname>Cohen</surname> <given-names>B</given-names></name><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>Rahbar</surname> <given-names>R</given-names></name><name><surname>Martin</surname> <given-names>B</given-names></name><name><surname>Murakami</surname> <given-names>K</given-names></name><name><surname>Lamorte</surname> <given-names>S</given-names></name><name><surname>Thompson</surname> <given-names>P</given-names></name><name><surname>Berman</surname> <given-names>H</given-names></name><name><surname>Zúñiga-Pflücker</surname> <given-names>JC</given-names></name><name><surname>Ohashi</surname> <given-names>PS</given-names></name><name><surname>Reedijk</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Notch shapes the innate immunophenotype in breast Cancer</article-title><source>Cancer Discovery</source><volume>7</volume><fpage>1320</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0037</pub-id><pub-id pub-id-type="pmid">28790030</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>Q</given-names></name><name><surname>Godschalk</surname> <given-names>RWL</given-names></name><name><surname>van Schooten</surname> <given-names>FJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inflammation and the chemical carcinogen benzo[a]pyrene: partners in crime</article-title><source>Mutation Research/Reviews in Mutation Research</source><volume>774</volume><fpage>12</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.mrrev.2017.08.003</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sikder</surname> <given-names>H</given-names></name><name><surname>Huso</surname> <given-names>DL</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>B</given-names></name><name><surname>Ryu</surname> <given-names>B</given-names></name><name><surname>Hwang</surname> <given-names>ST</given-names></name><name><surname>Powell</surname> <given-names>JD</given-names></name><name><surname>Alani</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors</article-title><source>Cancer Cell</source><volume>4</volume><fpage>291</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00245-9</pub-id><pub-id pub-id-type="pmid">14585356</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sistigu</surname> <given-names>A</given-names></name><name><surname>Yamazaki</surname> <given-names>T</given-names></name><name><surname>Vacchelli</surname> <given-names>E</given-names></name><name><surname>Chaba</surname> <given-names>K</given-names></name><name><surname>Enot</surname> <given-names>DP</given-names></name><name><surname>Adam</surname> <given-names>J</given-names></name><name><surname>Vitale</surname> <given-names>I</given-names></name><name><surname>Goubar</surname> <given-names>A</given-names></name><name><surname>Baracco</surname> <given-names>EE</given-names></name><name><surname>Remédios</surname> <given-names>C</given-names></name><name><surname>Fend</surname> <given-names>L</given-names></name><name><surname>Hannani</surname> <given-names>D</given-names></name><name><surname>Aymeric</surname> <given-names>L</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Niso-Santano</surname> <given-names>M</given-names></name><name><surname>Kepp</surname> <given-names>O</given-names></name><name><surname>Schultze</surname> <given-names>JL</given-names></name><name><surname>Tüting</surname> <given-names>T</given-names></name><name><surname>Belardelli</surname> <given-names>F</given-names></name><name><surname>Bracci</surname> <given-names>L</given-names></name><name><surname>La Sorsa</surname> <given-names>V</given-names></name><name><surname>Ziccheddu</surname> <given-names>G</given-names></name><name><surname>Sestili</surname> <given-names>P</given-names></name><name><surname>Urbani</surname> <given-names>F</given-names></name><name><surname>Delorenzi</surname> <given-names>M</given-names></name><name><surname>Lacroix-Triki</surname> <given-names>M</given-names></name><name><surname>Quidville</surname> <given-names>V</given-names></name><name><surname>Conforti</surname> <given-names>R</given-names></name><name><surname>Spano</surname> <given-names>JP</given-names></name><name><surname>Pusztai</surname> <given-names>L</given-names></name><name><surname>Poirier-Colame</surname> <given-names>V</given-names></name><name><surname>Delaloge</surname> <given-names>S</given-names></name><name><surname>Penault-Llorca</surname> <given-names>F</given-names></name><name><surname>Ladoire</surname> <given-names>S</given-names></name><name><surname>Arnould</surname> <given-names>L</given-names></name><name><surname>Cyrta</surname> <given-names>J</given-names></name><name><surname>Dessoliers</surname> <given-names>MC</given-names></name><name><surname>Eggermont</surname> <given-names>A</given-names></name><name><surname>Bianchi</surname> <given-names>ME</given-names></name><name><surname>Pittet</surname> <given-names>M</given-names></name><name><surname>Engblom</surname> <given-names>C</given-names></name><name><surname>Pfirschke</surname> <given-names>C</given-names></name><name><surname>Préville</surname> <given-names>X</given-names></name><name><surname>Uzè</surname> <given-names>G</given-names></name><name><surname>Schreiber</surname> <given-names>RD</given-names></name><name><surname>Chow</surname> <given-names>MT</given-names></name><name><surname>Smyth</surname> <given-names>MJ</given-names></name><name><surname>Proietti</surname> <given-names>E</given-names></name><name><surname>André</surname> <given-names>F</given-names></name><name><surname>Kroemer</surname> <given-names>G</given-names></name><name><surname>Zitvogel</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy</article-title><source>Nature Medicine</source><volume>20</volume><fpage>1301</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1038/nm.3708</pub-id><pub-id pub-id-type="pmid">25344738</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiotto</surname> <given-names>MT</given-names></name><name><surname>Banh</surname> <given-names>A</given-names></name><name><surname>Papandreou</surname> <given-names>I</given-names></name><name><surname>Cao</surname> <given-names>H</given-names></name><name><surname>Galvez</surname> <given-names>MG</given-names></name><name><surname>Gurtner</surname> <given-names>GC</given-names></name><name><surname>Denko</surname> <given-names>NC</given-names></name><name><surname>Le</surname> <given-names>QT</given-names></name><name><surname>Koong</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth</article-title><source>Cancer Research</source><volume>70</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2747</pub-id><pub-id pub-id-type="pmid">20028872</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strachan</surname> <given-names>DC</given-names></name><name><surname>Ruffell</surname> <given-names>B</given-names></name><name><surname>Oei</surname> <given-names>Y</given-names></name><name><surname>Bissell</surname> <given-names>MJ</given-names></name><name><surname>Coussens</surname> <given-names>LM</given-names></name><name><surname>Pryer</surname> <given-names>N</given-names></name><name><surname>Daniel</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8<sup>+</sup> T cells</article-title><source>OncoImmunology</source><volume>2</volume><elocation-id>e26968</elocation-id><pub-id pub-id-type="doi">10.4161/onci.26968</pub-id><pub-id pub-id-type="pmid">24498562</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suggitt</surname> <given-names>M</given-names></name><name><surname>Bibby</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>50 years of preclinical anticancer drug screening: empirical to target-driven approaches</article-title><source>Clinical Cancer Research</source><volume>11</volume><fpage>971</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">15709162</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sujobert</surname> <given-names>P</given-names></name><name><surname>Trautmann</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Conflicting signals for Cancer treatment</article-title><source>Cancer Research</source><volume>76</volume><fpage>6768</fpage><lpage>6773</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1393</pub-id><pub-id pub-id-type="pmid">27872099</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumimoto</surname> <given-names>H</given-names></name><name><surname>Imabayashi</surname> <given-names>F</given-names></name><name><surname>Iwata</surname> <given-names>T</given-names></name><name><surname>Kawakami</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells</article-title><source>The Journal of Experimental Medicine</source><volume>203</volume><fpage>1651</fpage><lpage>1656</lpage><pub-id pub-id-type="doi">10.1084/jem.20051848</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname> <given-names>H</given-names></name><name><surname>Mohr</surname> <given-names>U</given-names></name><name><surname>Kimmerle</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Spontaneous endocrine tumors in Sprague-Dawley rats</article-title><source>Journal of Cancer Research and Clinical Oncology</source><volume>95</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1007/BF00401012</pub-id><pub-id pub-id-type="pmid">521452</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname> <given-names>M</given-names></name><name><surname>Iwamoto</surname> <given-names>T</given-names></name><name><surname>Nakashima</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Proliferation and neoplastic transformation of pigment cells in metallothionein/ret transgenic mice</article-title><source>Pigment Cell Research</source><volume>5</volume><fpage>344</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0749.1992.tb00560.x</pub-id><pub-id pub-id-type="pmid">1292018</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talmadge</surname> <given-names>JE</given-names></name><name><surname>Singh</surname> <given-names>RK</given-names></name><name><surname>Fidler</surname> <given-names>IJ</given-names></name><name><surname>Raz</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Murine models to evaluate novel and conventional therapeutic strategies for Cancer</article-title><source>The American Journal of Pathology</source><volume>170</volume><fpage>793</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.060929</pub-id><pub-id pub-id-type="pmid">17322365</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannock</surname> <given-names>IF</given-names></name></person-group><year iso-8601-date="1968">1968</year><article-title>The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour</article-title><source>British Journal of Cancer</source><volume>22</volume><fpage>258</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/bjc.1968.34</pub-id><pub-id pub-id-type="pmid">5660132</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannock</surname> <given-names>IF</given-names></name></person-group><year iso-8601-date="1970">1970</year><article-title>Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor</article-title><source>Cancer Research</source><volume>30</volume><fpage>2470</fpage><lpage>2476</lpage><pub-id pub-id-type="pmid">4097429</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomlinson</surname> <given-names>RH</given-names></name><name><surname>Gray</surname> <given-names>LH</given-names></name></person-group><year iso-8601-date="1955">1955</year><article-title>The histological structure of some human lung cancers and the possible implications for radiotherapy</article-title><source>British Journal of Cancer</source><volume>9</volume><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1038/bjc.1955.55</pub-id><pub-id pub-id-type="pmid">13304213</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoreau</surname> <given-names>M</given-names></name><name><surname>Penny</surname> <given-names>HL</given-names></name><name><surname>Tan</surname> <given-names>K</given-names></name><name><surname>Regnier</surname> <given-names>F</given-names></name><name><surname>Weiss</surname> <given-names>JM</given-names></name><name><surname>Lee</surname> <given-names>B</given-names></name><name><surname>Johannes</surname> <given-names>L</given-names></name><name><surname>Dransart</surname> <given-names>E</given-names></name><name><surname>Le Bon</surname> <given-names>A</given-names></name><name><surname>Abastado</surname> <given-names>JP</given-names></name><name><surname>Tartour</surname> <given-names>E</given-names></name><name><surname>Trautmann</surname> <given-names>A</given-names></name><name><surname>Bercovici</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site</article-title><source>Oncotarget</source><volume>6</volume><fpage>27832</fpage><lpage>27846</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4940</pub-id><pub-id pub-id-type="pmid">26337837</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumeh</surname> <given-names>PC</given-names></name><name><surname>Harview</surname> <given-names>CL</given-names></name><name><surname>Yearley</surname> <given-names>JH</given-names></name><name><surname>Shintaku</surname> <given-names>IP</given-names></name><name><surname>Taylor</surname> <given-names>EJ</given-names></name><name><surname>Robert</surname> <given-names>L</given-names></name><name><surname>Chmielowski</surname> <given-names>B</given-names></name><name><surname>Spasic</surname> <given-names>M</given-names></name><name><surname>Henry</surname> <given-names>G</given-names></name><name><surname>Ciobanu</surname> <given-names>V</given-names></name><name><surname>West</surname> <given-names>AN</given-names></name><name><surname>Carmona</surname> <given-names>M</given-names></name><name><surname>Kivork</surname> <given-names>C</given-names></name><name><surname>Seja</surname> <given-names>E</given-names></name><name><surname>Cherry</surname> <given-names>G</given-names></name><name><surname>Gutierrez</surname> <given-names>AJ</given-names></name><name><surname>Grogan</surname> <given-names>TR</given-names></name><name><surname>Mateus</surname> <given-names>C</given-names></name><name><surname>Tomasic</surname> <given-names>G</given-names></name><name><surname>Glaspy</surname> <given-names>JA</given-names></name><name><surname>Emerson</surname> <given-names>RO</given-names></name><name><surname>Robins</surname> <given-names>H</given-names></name><name><surname>Pierce</surname> <given-names>RH</given-names></name><name><surname>Elashoff</surname> <given-names>DA</given-names></name><name><surname>Robert</surname> <given-names>C</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title><source>Nature</source><volume>515</volume><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/nature13954</pub-id><pub-id pub-id-type="pmid">25428505</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Dyke</surname> <given-names>T</given-names></name><name><surname>Jacks</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cancer modeling in the modern era: progress and challenges</article-title><source>Cell</source><volume>108</volume><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)00621-9</pub-id><pub-id pub-id-type="pmid">11832204</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname> <given-names>MG</given-names></name><name><surname>Cantley</surname> <given-names>LC</given-names></name><name><surname>Thompson</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Understanding the warburg effect: the metabolic requirements of cell proliferation</article-title><source>Science</source><volume>324</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varticovski</surname> <given-names>L</given-names></name><name><surname>Hollingshead</surname> <given-names>MG</given-names></name><name><surname>Robles</surname> <given-names>AI</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Cherry</surname> <given-names>J</given-names></name><name><surname>Munroe</surname> <given-names>DJ</given-names></name><name><surname>Lukes</surname> <given-names>L</given-names></name><name><surname>Anver</surname> <given-names>MR</given-names></name><name><surname>Carter</surname> <given-names>JP</given-names></name><name><surname>Borgel</surname> <given-names>SD</given-names></name><name><surname>Stotler</surname> <given-names>H</given-names></name><name><surname>Bonomi</surname> <given-names>CA</given-names></name><name><surname>Nunez</surname> <given-names>NP</given-names></name><name><surname>Hursting</surname> <given-names>SD</given-names></name><name><surname>Qiao</surname> <given-names>W</given-names></name><name><surname>Deng</surname> <given-names>CX</given-names></name><name><surname>Green</surname> <given-names>JE</given-names></name><name><surname>Hunter</surname> <given-names>KW</given-names></name><name><surname>Merlino</surname> <given-names>G</given-names></name><name><surname>Steeg</surname> <given-names>PS</given-names></name><name><surname>Wakefield</surname> <given-names>LM</given-names></name><name><surname>Barrett</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast Cancer models</article-title><source>Clinical Cancer Research</source><volume>13</volume><fpage>2168</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0918</pub-id><pub-id pub-id-type="pmid">17404101</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Waddington</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1957">1957</year><source>The Strategy of the Genes; a Discussion of Some Aspects of Theoretical Biology</source><publisher-loc>London</publisher-loc><publisher-name>Allen &amp; Unwin</publisher-name></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname> <given-names>O</given-names></name><name><surname>Wind</surname> <given-names>F</given-names></name><name><surname>Negelein</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1927">1927</year><article-title>The metabolism of tumors in the body</article-title><source>The Journal of General Physiology</source><volume>8</volume><fpage>519</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1085/jgp.8.6.519</pub-id><pub-id pub-id-type="pmid">19872213</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname> <given-names>SK</given-names></name><name><surname>Egilmez</surname> <given-names>NK</given-names></name><name><surname>Suttles</surname> <given-names>J</given-names></name><name><surname>Stout</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo</article-title><source>The Journal of Immunology</source><volume>178</volume><fpage>1357</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.3.1357</pub-id><pub-id pub-id-type="pmid">17237382</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waxler</surname> <given-names>SH</given-names></name><name><surname>Tabar</surname> <given-names>P</given-names></name><name><surname>Melcher</surname> <given-names>LR</given-names></name></person-group><year iso-8601-date="1953">1953</year><article-title>Obesity and the time of appearance of spontaneous mammary carcinoma in C3H mice</article-title><source>Cancer Research</source><volume>13</volume><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">13042818</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname> <given-names>JM</given-names></name><name><surname>Subleski</surname> <given-names>JJ</given-names></name><name><surname>Wigginton</surname> <given-names>JM</given-names></name><name><surname>Wiltrout</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Immunotherapy of Cancer by IL-12-based cytokine combinations</article-title><source>Expert Opinion on Biological Therapy</source><volume>7</volume><fpage>1705</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1517/14712598.7.11.1705</pub-id><pub-id pub-id-type="pmid">17961093</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname> <given-names>JM</given-names></name><name><surname>Guérin</surname> <given-names>MV</given-names></name><name><surname>Regnier</surname> <given-names>F</given-names></name><name><surname>Renault</surname> <given-names>G</given-names></name><name><surname>Galy-Fauroux</surname> <given-names>I</given-names></name><name><surname>Vimeux</surname> <given-names>L</given-names></name><name><surname>Feuillet</surname> <given-names>V</given-names></name><name><surname>Peranzoni</surname> <given-names>E</given-names></name><name><surname>Thoreau</surname> <given-names>M</given-names></name><name><surname>Trautmann</surname> <given-names>A</given-names></name><name><surname>Bercovici</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression</article-title><source>OncoImmunology</source><volume>6</volume><elocation-id>e1346765</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2017.1346765</pub-id><pub-id pub-id-type="pmid">29123960</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellenstein</surname> <given-names>MD</given-names></name><name><surname>de Visser</surname> <given-names>KE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cancer-Cell-Intrinsic mechanisms shaping the tumor immune landscape</article-title><source>Immunity</source><volume>48</volume><fpage>399</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.004</pub-id><pub-id pub-id-type="pmid">29562192</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wexler</surname> <given-names>H</given-names></name><name><surname>Minton</surname> <given-names>JP</given-names></name><name><surname>Ketcham</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="1965">1965</year><article-title>A comparison of survival time and extent of tumor metastases in mice with transplanted, induced and spontaneous tumors</article-title><source>Cancer</source><volume>18</volume><fpage>985</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(196508)18:8&lt;985::AID-CNCR2820180810&gt;3.0.CO;2-P</pub-id><pub-id pub-id-type="pmid">14326497</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willimsky</surname> <given-names>G</given-names></name><name><surname>Blankenstein</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance</article-title><source>Nature</source><volume>437</volume><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/nature03954</pub-id><pub-id pub-id-type="pmid">16136144</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willimsky</surname> <given-names>G</given-names></name><name><surname>Blankenstein</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The adaptive immune response to sporadic Cancer</article-title><source>Immunological Reviews</source><volume>220</volume><fpage>102</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2007.00578.x</pub-id><pub-id pub-id-type="pmid">17979842</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1958">1958</year><article-title>Pathogenesis of metastasis formation observed in vivo in the rabbit ear chamber</article-title><source>A.M.A. Archives of Pathology</source><volume>66</volume><fpage>550</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">13582395</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>X</given-names></name><name><surname>McCarrick</surname> <given-names>J</given-names></name><name><surname>Jewett</surname> <given-names>L</given-names></name><name><surname>Knowles</surname> <given-names>BB</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice</article-title><source>PNAS</source><volume>91</volume><fpage>3916</fpage><lpage>3920</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.9.3916</pub-id><pub-id pub-id-type="pmid">8171012</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeiser</surname> <given-names>R</given-names></name><name><surname>Schnitzler</surname> <given-names>M</given-names></name><name><surname>Andrlova</surname> <given-names>H</given-names></name><name><surname>Hellige</surname> <given-names>T</given-names></name><name><surname>Meiss</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Immunotherapy for malignant melanoma</article-title><source>Current Stem Cell Research &amp; Therapy</source><volume>7</volume><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.2174/157488812799859883</pub-id><pub-id pub-id-type="pmid">22329580</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Ji</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Qin</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of angiogenesis in pancreatic Cancer biology and therapy</article-title><source>Biomedicine &amp; Pharmacotherapy</source><volume>108</volume><fpage>1135</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.09.136</pub-id><pub-id pub-id-type="pmid">30372814</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Powis de Tenbossche</surname> <given-names>CG</given-names></name><name><surname>Cané</surname> <given-names>S</given-names></name><name><surname>Colau</surname> <given-names>D</given-names></name><name><surname>van Baren</surname> <given-names>N</given-names></name><name><surname>Lurquin</surname> <given-names>C</given-names></name><name><surname>Schmitt-Verhulst</surname> <given-names>AM</given-names></name><name><surname>Liljeström</surname> <given-names>P</given-names></name><name><surname>Uyttenhove</surname> <given-names>C</given-names></name><name><surname>Van den Eynde</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Resistance to Cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1404</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00784-1</pub-id><pub-id pub-id-type="pmid">29123081</pub-id></element-citation></ref></ref-list></back></article>